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The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide
practical recommendations on the management of HIV-1 infection in children in Europe and are
an update to those published in 2009. Aims of treatment have progressed significantly over the
last decade, moving far beyond limitation of short-term morbidity and mortality to optimizing
health status for adult life and minimizing the impact of chronic HIV infection on immune
system development and health in general. Additionally, there is a greater need for increased
awareness and minimization of long-term drug toxicity. The main updates to the previous
guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at
all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical
indications), revised guidance on first- and second-line ART recommendations, including more
recently available drug classes, expanded guidance on management of coinfections (including
tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as
they approach transition to adult services. There is a new section on the current ART ‘pipeline’
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of drug development, a comprehensive summary table of currently recommended ART with
dosing recommendations. Differences between PENTA and current US and World Health
Organization guidelines are highlighted and explained.
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1. Introduction
• These guidelines apply to children with HIV-1 infection
in Europe.
• Thresholds for starting antiretroviral therapy (ART) have
changed as continuing improvements in treatment
mean that the objectives of ART should increasingly be
optimizing health status for a full and productive adult
life rather than just survival.
• New drugs have been incorporated into the guideline as
first- and second-line options.
The 2015 Paediatric European Network for Treatment of
AIDS (PENTA) guidelines have been updated from those of
2009 [1], and make recommendations based on a shift in
aims of treatment away from minimization of short-term
morbidity and mortality towards optimizing immune status
and general health for a full and productive adult life. This
mirrors the general trend in global treatment guidelines
that now include higher CD4 thresholds for ART initiation
and an increased number of clinical indications in both
adults and children [2–6].
The aim is to provide a practical guide to treatment
rather than a comprehensive review of all the evidence
on ART in children. More detailed information for
resource-rich and resource-poor settings is available
from recently updated US [4] and World Health Organi-
zation (WHO) [6] paediatric guidelines. Special considera-
tions for children in resource-limited settings where
background rates of concomitant infections and malnu-
trition are much higher are not considered here, and
the reader is referred to WHO guidelines. Differences
from the WHO and US Department of Health and Human
Services (DHHS) guidelines will be referred to where
relevant in the document and are summarized in
Table 1.
Licensing of newer drugs in children and the availability
of more appropriate formulations have allowed inclusion
of a larger number of drug options at different ages. These
drugs, with limited data on long-term toxicity, are included
with the caveat that clinicians should be vigilant for signs
of adverse effects and fully counsel children and families
regarding what is known and unknown about long-term
use of newer drugs.
Table 1 Comparison of current World Health Organization (WHO), US Department of Health and Human Services (DHHS) and Paediatric European
Network for Treatment of AIDS (PENTA) guidelines for antiretroviral therapy (ART) initiation
WHO 2013 DHHS 2014 PENTA 2015
< 1 year All All All
1–3 years All
Prioritize:
1–2 years
WHO stage 3/4
CD4 count ≤ 750 cells/μL
CD4 percentage ≤ 25%
CD4 count < 1000 cells/μL
CD4 percentage < 25%
CDC category B/C
HIV VL > 100 000 copies/ml
Consider:
All
CD4 count ≤ 1000 cells/μL
CD4 percentage ≤ 25%
WHO stage 3/4
CDC category B/C
Consider:
All*
3–5 years All
Prioritize:
WHO stage 3/4
CD4 count ≤ 750 cells/μL
CD4 percentage ≤ 25%
CD4 count < 750 cells/μL
CD4 percentage < 25%
CDC category B/C
HIV VL > 100 000 copies/ml
Consider:
All
CD4 count ≤ 750 cells/μL
CD4 percentage ≤ 25%
WHO stage 3/4
CDC category B/C
Consider:
HIV VL > 100 000 copies/ml
> 5 years CD4 ≤ 500 cells/μL
Prioritize:
WHO stage 3/4
CD4 count ≤ 350 cells/μL
CD4 count < 500 cells/μL
CDC category B/C
HIV VL > 100 000 copies/ml
Consider:
All
CD4 count ≤ 350 cells/μL
WHO stage 3/4
CDC category B/C
Consider:
CD4 count ≤ 500 cells/μL
HIV VL > 100 000 copies/ml
This table summarizes the main immunological, virological and clinical indications and is not exhaustive.
‘All’, all children irrespective of immunological status; CDC, Centers for Disease Control and Prevention; VL, viral load.
*In children aged 1–3 years consider ART in all especially if VL > 100 000 copies/ml.
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Much of the new paediatric data (published since 2009)
that have been used to inform the 2015 PENTA guidelines
have come from non-European settings and therefore must
be considered with caution when applied to European
cohorts. As with previous versions of the guidelines, there
remains a paucity of data from randomized controlled trials
(RCTs) on which to base European paediatric ART guide-
lines. Therefore, we continue to rely on cohort studies,
extrapolation from adult data, and expert opinion. Wher-
ever possible, children should be entered into clinical trials.
The guidelines have been developed using a similar
method to that used for the adult European AIDS Clinical
Society (EACS) guidelines [3,7]. A panel of experts
reviewed the published literature and formulated the main
recommendations. The full PENTA Steering Committee
then reviewed and refined the recommendations until con-
sensus was reached. This approach has recently been criti-
cized by some. Latest WHO and British HIV Association
(BHIVA) guidelines have now moved to using the struc-
tured Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) system [7]. It is the opinion
of PENTA that the paucity of RCT evidence means that the
GRADE system would not provide sufficient additional
benefit to the guidelines’ development to justify its use and
therefore the writing group has elected to continue using
the less formalized system described above.
PENTA guidelines seek to optimize treatment for chil-
dren in Europe. However, particularly during adolescence,
care may need to be individualized. This document should
not be seen as a standard for litigation as individualization
of case management and departure from this guidance may
be necessary and indicated.
Significant changes since the 2009 guidelines include:
• decreased frequency of laboratory monitoring in clini-
cally stable children both on and off ART;
• consideration of ART initiation in all children aged 1–3
years in order to minimize the risks of disease progres-
sion or death;
• consideration of ART initiation at higher CD4 thresholds
in children > 5 years of age in order to optimize potential
for immune reconstitution;
• additional clinical indications for ART initiation at all
ages;
• addition of newer protease and integrase inhibitors to
first-line preferred and alternative third agent options,
respectively;
• update on specific guidance in the context of hepatitis B
and C virus and tuberculosis (TB) coinfection in light of
new ART options at younger ages;
• a summary of new drugs [including new fixed dose
combinations (FDCs)] that can be considered for second-
and third-line options and of the ‘pipeline’ of new drugs
likely to become available;
• an emphasis on the needs of older children and adoles-
cents as they approach transition to adult care;
• an updated drug dosing table including all currently
recommended licensed antiretroviral drugs for children.
2. Summary of recommendations
3. Diagnosis, baseline investigations and
pretreatment monitoring
• If a woman is diagnosed with HIV infection, all of her
children potentially at risk of infection should be tested
for HIV irrespective of age.
• Children under 18 months of age at risk of perinatally
acquired HIV infection should be tested using blood
DNA or RNA polymerase chain reaction (PCR) with sub-
sequent confirmatory repeat PCR if positive.
• Post-exposure prophylaxis (PEP) should be given for
4−6 weeks to all babies born to HIV-infected mothers
according to local guidelines.
• Babies born to HIV-infected mothers should have an HIV
RNA PCR test at birth and at least two further separate
PCR tests (the first 2 weeks after cessation of PEP, and
the second at least 6 weeks after cessation of PEP). For
babies with high risk of transmission, an additional PCR
test midway through PEP is recommended.
• Breast feeding is not recommended. In circumstances in
which the mother is choosing to breast feed against
recommendations, the baby should have regular screen-
ing PCR tests. Two negative HIV RNA PCR tests (2 and 6
weeks after cessation of breast feeding) are required to
confirm that the baby is not infected.
• Children over 18 months of age can be tested using
serological assays with subsequent confirmatory PCR if
positive or equivocal.
• A negative serological test in children who have had a
positive HIV RNA PCR test does not exclude ongoing
HIV infection.
• A detailed history of any possible previous ART given to
the child and/or mother (or other likely source of infec-
tion) should be documented.
• The genotypic HIV resistance profile should be docu-
mented at baseline.
• The human leucocyte antigen (HLA) B*5701 genotype
should be confirmed negative before using abacavir (ABC).
• Clinical assessment should be carried out 3−4-monthly
in children who are stable off ART, with frequency of
laboratory monitoring dictated by age, clinical status and
proximity to thresholds for ART initiation [minimum
6-monthly HIV viral load (VL) and CD4 count].
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• Local guidelines for bacillus Calmette−Guérin (BCG)
immunization of babies of HIV-infected mothers should
be followed. HIV-exposed infants at low risk of HIV
transmission (maternal VL < 50 HIV-1 RNA copies/ml
at or after 36 weeks of gestation) with high risk of TB
exposure may receive BCG vaccination at birth, prior to
definitive diagnosis/exclusion of HIV infection.
4. Prophylaxis against opportunistic infections
• Prophylaxis against Pneumocystis jirovecii pneumonia
(PJP) should be given to all HIV-infected infants from
age 1 month and to older children with low CD4 counts:
in children aged 1–4 years, CD4 count < 500 cells/μL or
< 15%; in children aged ≥ 5 years, CD4 count < 200 cells/μl
or < 15%. Co-trimoxazole is the drug of first choice (see
drug table in Supplementary Table S1 for dosing).
• Routine primary prophylaxis against other infections is
not recommended.
5. When to start ART
ART is recommended:
• in all children under 1 year of age;
• in all children with significant disease [WHO stage 3 or
4 or Centers for Disease Control and Prevention (CDC)
stage B or C];
• in asymptomatic children over 1 year of age based on
age-specific CD4 count thresholds;
• to be initiated before the CD4 count reaches the CD4
treatment threshold;
• in those with hepatitis C virus (HCV) or active TB
coinfection.
ART should be considered:
• in asymptomatic children over 5 years of age at CD4
counts of 350–500 cells/μl, to potentially optimize CD4
count in adulthood;
• in children with high VL (> 100 000 copies/ml);
• in asymptomatic children aged 1–3 years irrespective of
immune status and VL;
• in sexually active adolescents, to minimize the risk of
onward transmission;
• in the presence of any significant HIV-related clinical
symptoms;
• in hepatitis B virus (HBV) coinfection irrespective of
immune status.
6. Which ART regimen to start as first-line therapy
• Children should start effective (at least three drugs)
ART, usually a dual or triple nucleoside reverse
transcriptase inhibitor (NRTI) backbone together with
either a ritonavir-boosted protease inhibitor (PI) or a
nonnucleoside reverse transcriptase inhibitor (NNRTI).
• Children exposed to nevirapine (NVP) during failed pre-
vention of mother-to-child transmission (PMTCT) (or in
whom perinatal NVP exposure cannot be excluded)
should be started on a boosted PI-containing regimen as
transmitted resistance may lead to failure of NVP-
containing ART.
• Children aged < 3 years not exposed to NVP during failed
PMTCT may be initiated on either NVP or ritonavir-
boosted lopinavir (LPV/r)-containing ART. We recom-
mend that NVP should be given together with three NRTIs
[ABC, lamivudine (3TC) and zidovudine (ZDV)] in all
infants and in children aged 1–3 years with VL > 100 000
copies/ml or signs of central nervous system (CNS)
involvement as an induction-maintenance strategy,
unless any of these drugs are contraindicated (such as
ABC in HLA B*5701-positive children).
• In children aged > 3 years, either NNRTI or boosted
PI-based ART is acceptable for initial therapy. Factors
such as availability of age-appropriate formulations, pal-
atability, dosing frequency and adherence should be
considered when choosing NNRTIs or boosted PIs.
• The preferred NNRTI is NVP in children aged < 3 years not
exposed to NVP during failed PMTCT, and efavirenz (EFV)
in children aged > 3 years. The preferred PI in children
aged < 6 years is LPV/r, in children aged 6−12 years it is
ritonavir-boosted atazanavir (ATV/r), and in children
aged > 12 years it is ATV/r or ritonavir-boosted darunavir
(DRV/r).
• Integrase inhibitor (INSTI)-based ART may be an alterna-
tive regimen in children over age 12 years.
• The preferred first-line NRTIs are ABC/3TC in children
aged < 12 years, and tenofovir/emtricitabine (TDF/FTC) or
ABC/3TC (if VL < 100 000 copies/ml) in children aged
> 12 years.
• Age, HLA B*5701 genotype, previous drug exposure,
resistance profile, coinfections, available formulations
and likely adherence should be taken into account when
choosing a first-line regimen.
• See Table 4 (later) for details of recommended first-line
ART regimens.
7. Adherence and HIV knowledge
• Adherence to treatment is paramount and should be
discussed at each clinic visit.
• Every effort should be made to simplify a regimen to
support adherence (e.g. using once-daily regimens, FDCs,
and ‘forgiving’ regimens with higher barriers to resistance).
Simple adherence aids should be used when appropriate.
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• Children should know of their HIV diagnosis before
adolescence.
• Monitoring for psychological, neurocognitive and mental
health issues should be routine, allowing early supportive
and therapeutic intervention.
8. Monitoring on ART
• The aim of ART is to achieve an undetectable VL (< 50
copies/ml) and CD4 reconstitution.
• Laboratory monitoring for drug toxicity should be
performed initially within 2–4 weeks of starting a new
drug, then at least every 6 months if there are no
ongoing toxicity concerns.
• After starting ART, VL should be checked early (at
around 1 month) to confirm that VL is decreasing (this
can coincide with toxicity monitoring).
• VL and CD4 count can then be monitored approximately
every 3–4 months once the patient has been established
on treatment.
• Once CD4 cells are reconstituted and VL has been < 50
copies/ml consistently for over 1 year, CD4 parameters
can be monitored less frequently (every 6–8 months, i.e.
at alternate clinic visits).
• More frequent clinical and laboratory monitoring is
required:
• in infancy;
• if adherence is poor;
• soon after starting or changing therapy (e.g. liver
function tests should be performed within 2 weeks);
• in the context of ongoing drug toxicity;
• when giving medications with significant drug inter-
actions with ART such as antituberculous therapy.
9. Drug toxicities and interactions
• Toxicities depend on the individual drugs and ART
combination and should be assessed at each clinic
visit.
• Drug interactions should be considered when starting
new medications in a child on ART. Use http://www.hiv
-druginteractions.org/ to check drug interactions and
toxicities.
• See Table 5 (later) for common ART-associated toxicities.
10. Coinfections
Hepatitis B virus and hepatitis C virus
• Liver disease in children with HBV or HCV coinfection
should be managed jointly with paediatric experts in
viral hepatitis.
• HCV coinfection is an indication for starting ART.
• For HBV coinfection, if treatment of HIV infection is not
indicated and there is no evidence of liver disease, HIV
treatment should be considered but may be deferred.
Tuberculosis
• All HIV-infected children exposed to an individual with
infectious TB and all children with evidence of latent TB
infection should have preventive TB treatment (once
active TB disease has been excluded).
• In children with active TB disease, TB treatment should
be started at TB diagnosis. ART should be started, as
soon as practicable, and within 2 and 8 weeks of TB
treatment in children with severe and moderate immu-
nosuppression, respectively. ART may be deferred at
higher CD4 counts until TB treatment is completed.
• There is significant interaction between ART and TB
therapy. Therapeutic drug monitoring (TDM), where
available, should be used in the context of potential
significant interactions.
• Children with TB coinfection should be managed in
consultation with an expert in the treatment of paedi-
atric TB. A specialist in drug-resistant TB (DRTB) should
be involved in the management of DRTB contacts and
cases.
• See Table 6 (later) for ART choices in children with TB.
Opportunistic infections
• We recommend that ART should be initiated as early as
possible, apart from in the context of cryptococcal men-
ingitis, where evidence in adults has shown that delay-
ing ART may be associated with reduced mortality.
11. When to switch, resistance testing and second and
subsequent ART regimens
ART regimens may be changed because of treatment
failure, because of toxicity or for simplification.
Virological failure – second and subsequent regimens
• Switching to second-line therapy following virological
failure should occur early (VL > 1000 copies/ml) for
those failing on combinations including drugs with a
low genetic barrier to resistance [NNRTIs or raltegravir
(RAL)].
• Where there are blips in VL (detectable VL < 400 copies/
ml), blood tests should be repeated within 4 weeks to
confirm re-suppression.
• Reinforcement of adherence support, as the main reason
for treatment failure, should be prioritized. Switching
treatment when there are ongoing problems with adher-
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ART.
• Table 7 (see later) summarizes potential strategies for
choosing second-line therapy. If the suggested options
are not applicable, seek expert advice.
Resistance testing
• Resistance testing should be performed prior to switching
regimens when there is virological failure. Resistance
testing should be undertaken while the patient is still on
the failing regimen. If this is not possible, ideally test
for resistance within 4 weeks of stopping the failing
regimen.
• Resistance testing may include reverse transcriptase/
protease/integrase/V3 loop/envelope sequencing.
• The interpretation of resistance results can be guided by
the Stanford HIV Drug Resistance Database (http://
hivdb.stanford.edu/).
• Substituting single drugs in a failing regimen without
prior resistance testing is not recommended.
Simplification
• Where possible, regimens should be simplified (once-
daily and fixed dose combinations), but switching to
NNRTI-based regimens or PI monotherapy is not advised
if there are adherence issues.
12. Stopping treatment and treatment interruption
• Treatment interruptions cannot be routinely recom-
mended and starting ART currently means lifelong
therapy.
• Judicious use of planned treatment interruptions may
be considered in circumstances when ART needs to be
stopped such as because of toxicity or adherence diffi-
culties, while the latter is being addressed.
• Stopping NNRTIs when HIV is fully suppressed requires
a replacement or staggered stop to reduce the risk of
developing NNRTI resistance as a result of the longer
half-life of NNRTIs. A replacement stop is preferable.
13. Adolescence, mental health and transition
• Adolescents commencing first-line therapy should be
started on boosted PI-based ART and subsequently
switch to NNRTI-based ART once adherence has been
established and VL is consistently < 50 copies/ml.
• Multidisciplinary monitoring for signs of psychological
distress and mental health disorder should be routine
as children progress through adolescence towards
transition.
• Early and ongoing support from clinical psychologists
with specialist paediatric knowledge is recommended.
14. Pipeline and upcoming trials
See Table 8.
3. Diagnosis, baseline investigations and
pretreatment monitoring
• If a mother is diagnosed with HIV infection, all children
potentially at risk of infection should be tested for HIV
irrespective of age.
• Children under 18 months of age at risk of perinatally
acquired HIV infection should be tested using blood
DNA or RNA PCR with subsequent confirmatory repeat
PCR if positive.
• PEP should be given for 4–6 weeks to all babies born to
HIV-infected mothers according to local guidelines.
• Babies born to HIV-infected mothers should have an HIV
RNA PCR test at birth and at least two further separate
PCR tests (the first 2 weeks after cessation of PEP, and
the second at least 6 weeks after cessation of PEP). For
babies at high risk of transmission, an additional PCR
test midway through PEP is recommended.
• Breast feeding is not recommended. In circumstances in
which the mother is choosing to breast feed against
recommendations, the baby should have regular screen-
ing PCR tests. Two negative HIV RNA PCR tests (2 and 6
weeks after cessation of breast feeding) are required to
confirm that the baby is not infected.
• Children over 18 months of age can be tested using
serological assays with subsequent confirmatory PCR if
positive or equivocal.
• A negative serological test in children who have had
positive HIV RNA PCR does not exclude ongoing HIV
infection.
• A detailed history of any possible previous ART given to
the child and/or mother (or other likely source of infec-
tion) should be documented.
• The genotypic HIV resistance profile should be docu-
mented at baseline.
• The HLA B*5701 genotype should be confirmed negative
before using ABC.
• Clinical assessment should be carried out 3−4-monthly
in children who are stable off ART, with frequency
of laboratory monitoring dictated by age, clinical
status and proximity to thresholds for ART initiation
(minimum 6-monthly HIV VL and CD4 count).
• Local guidelines for BCG immunization of babies of
HIV-infected mothers should be followed. HIV-exposed
infants at low risk of HIV transmission (maternal
6 A Bamford, et al.
© 2015 British HIV Association HIV Medicine (2018), 19, 1-- 42e e
e
VL < 50 copies/ml at or after 36 weeks of gestation) with
high risk of TB exposure may receive BCG vaccination at
birth, prior to definitive diagnosis/exclusion of HIV
infection.
3.1 Confirmation of HIV diagnosis
Optimal treatment of HIV infection in children depends
upon timely diagnosis. This requires early HIV testing of all
infants born to HIV-infected women and prompt testing of
infants or older children at risk or with symptoms or signs
of HIV infection. Infants born to women with HIV infection
will be HIV antibody positive because of transplacental
transfer of maternal antibodies. An HIV PCR test is needed
to confirm or exclude the diagnosis. Either HIV RNA or
DNA PCR may be used, depending on local availability
[8–12]. PEP should be given for 4–6 weeks to all babies
born to HIV-infected mothers according to local guidelines.
A PCR test should be performed at birth. At least two
positive PCR tests on separate samples from the baby
(not the umbilical cord) are required to confirm an HIV
diagnosis. A repeat test should be carried out as soon as
possible after any positive PCR test in an infant to avoid
delay in confirming the diagnosis and initiating treatment.
Up to 62% of HIV-infected neonates may have a negative
initial PCR test in the first 48 hours of life [12]. PCR tests
become more reliable 14–21 days after birth. The purpose
of the initial test at birth is thus to allow rapid identifica-
tion of those that are already positive so that a confirma-
tory test and treatment can be initiated without delay. Later
tests are essential for excluding HIV infection in babies
who test negative at birth.
In the absence of breast feeding, at least two separate
negative HIV RNA PCRs after stopping PEP are required to
confirm that an exposed baby is uninfected (the first 2
weeks after cessation of PEP, and the second at least 6
weeks after cessation of PEP). For babies born with high
risk of transmission, an additional PCR test midway
through PEP is recommended to allow earlier identification
of infected infants. The use of fourth-generation point-
of-care antibody/antigen testing for diagnosis of HIV
infection in children under 18 months of age is not rec-
ommended in view of low sensitivity for distinguishing
between HIV infection and positive serology from maternal
antibody [13]. Some less prevalent HIV subtypes may
escape detection by PCR (e.g. HIV A, C-H and O) [14]. Those
using PCR for diagnosis should know the sensitivity of the
assay being used for the likely subtype being tested for.
Expert advice should be sought if there is any doubt about
the interpretation of results. However, initiation of ART in
infants should not be unduly delayed by referrals to an
expert centre.
Babies of HIV-infected women may subsequently
become infected after initial negative tests if they are
breast-fed. Breast feeding is not recommended in high-
income countries, where alternative feeding is safe and
practical. If in exceptional circumstances an uninfected
baby is breast-fed, the mother should be on effective ART.
Two confirmatory PCR tests, 2 and 6 weeks after cessation
of breast feeding and PEP, are required to confirm that the
baby is not infected. It is important to note that HIV-
infected children who have commenced ART may become
seronegative by standard commercial testing after loss of
passively acquired maternal antibodies, especially after
early ART initiation (< 3–6 months of age) [15]. A negative
serological test in this context does not exclude ongoing
HIV infection as the HIV DNA PCR test remains positive.
Infants and children > 18 months of age who present
with symptoms consistent with HIV infection and
unknown maternal HIV status should initially have an HIV
antibody test. If this is positive, they will require a con-
firmatory PCR test. It is recommended that all previously
untested children of HIV-infected women should be
tested for HIV whatever their age, as infected children may
remain asymptomatic throughout childhood and adoles-
cence [16]. All siblings at risk of perinatally acquired
infection (irrespective of age) should also have an HIV test.
Adult physicians and family doctors should routinely ask
all HIV-infected men and women in their care if they have
children and refer those at risk for testing [17].
3.2 Baseline assessments once diagnosis has
been confirmed
Once a diagnosis of HIV infection has been confirmed,
children should be assessed clinically, including assessment
of growth and development, to allow staging of HIV infec-
tion according to WHO (or CDC) classifications [4,6].
To plan future ART, it is important to document whether
the child has been exposed to previous ART, in utero,
through breast feeding, as PEP or as therapy (e.g. in their
country of origin). If available, the antiretroviral history of
the mother or other source case should also be documented.
In view of the possibility of transmitted drug resistance
[18,19] and unreported prior ART exposure, HIV genotypic
resistance testing is recommended at baseline (including
reverse transcriptase, protease and integrase resistance
testing when available). If available, the results of resist-
ance testing of the source case, as close as possible to the
time of transmission, should also be documented. Baseline
viral co-receptor [C-C chemokine receptor type 5 (CCR5)]
tropism testing is not indicated, as CCR5 receptor antago-
nists are not currently recommended as first-line therapy.
Other baseline investigations after HIV diagnosis include
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measurements of HIV RNA VL and CD4 lymphocyte
percentage and absolute count, tests for other vertically
transmitted or postnatally acquired infections [infections
with HBV, HCV, toxoplasma, cytomegalovirus (CMV),
syphilis, TB and Chagas (in those at risk)], full blood count,
haemoglobinopathy screen (in risk groups), bone profile,
and tests of liver and renal function. Baseline echocardi-
ography in those at risk of cardiomyopathy should be
considered. HLA B*5701 testing, where available, is
recommended at baseline prior to starting ABC [20]. See
baseline investigations at http://www.chiva.org.uk for
further guidance.
A full vaccine history should be taken and if necessary
serology performed to confirm immunity and to aid in
decision making around catch-up and boosting [21]. Local
BCG practices for babies of HIV-infected mothers should be
followed. In areas of low TB incidence or if there is high
risk of HIV transmission, BCG vaccination should be post-
poned until an infant is confirmed as HIV negative. HIV-
exposed infants at low risk of HIV transmission (maternal
VL < 50 copies/ml at or after 36 weeks of gestation) with
high risk of TB exposure may receive BCG vaccination at
birth, prior to definitive diagnosis/exclusion of HIV infec-
tion [22]. The very low risk of HIV transmission with an
undetectable maternal VL means that in these circum-
stances the risk of severe TB from not vaccinating is greater
than the risk of HIV-related BCG complications. In
resource-poor settings with high TB prevalence, BCG vac-
cination is given to all infants prior to determination of
HIV status. Early ART in this context has been shown to
minimize the risk of BCG-related complications [23].
In those presenting outside the neonatal period, a base-
line chest radiograph allows assessment for respiratory
complications, including lymphoid interstitial pneumonitis
and TB. Infants and children with advanced HIV disease
should have an ophthalmic examination for evidence of
retinitis, and a blood CMV PCR test (if available). Infants
and children with evidence of neurological involvement
should undergo baseline neuroimaging. Additional base-
line immunological assessment for evidence of TB infec-
tion is recommended [tuberculin skin test (TST) and/or
interferon gamma release assay (IGRA)].
Children not yet requiring ART (see treatment criteria
below) should have clinical monitoring at intervals of no
longer than 3–4 months. Routine monitoring should include
clinical examination and measurement of growth param-
eters. Monitoring for HIV disease progression and compli-
cations using CD4 count/percentage and VL, renal and liver
function and urinalysis is recommended on a 6-monthly
basis, and should be performed more frequently in younger
children and those approaching treatment thresholds.
Annual assessment of neurodevelopment, blood pressure,
nutrition (including lipids) and puberty is also recom-
mended. Vitamin D should be assessed and managed
according to local guidelines as in HIV-uninfected children.
Less frequent assessment of these parameters has been
suggested in adult guidelines [2]. However, in view of the
possibility of more rapid disease progression in children, the
frequency of laboratory monitoring should remain as rec-
ommended above for children not receiving ART.
4. Prophylaxis against
opportunistic infections
• Prophylaxis against Pneumocystis jirovecii should be
given to all HIV-infected infants from age 1 month and
to older children with low CD4 counts (see criteria
below). Co-trimoxazole is the drug of first choice (see
drug table in Supplementary Table S1 for dosing).
• No routine primary prophylaxis against other infections
is recommended.
Prophylaxis with co-trimoxazole is highly effective at
preventing potentially life-threatening infection with
P. jirovecii, and also at reducing bacterial infections [24,25].
In view of their susceptibility to severe P. jirovecii infection,
all HIV-infected infants should receive prophylaxis from 4
weeks of age until their first birthday, regardless of CD4 and
VL [26]. HIV-exposed babies at high risk for transmission
should also commence P. jirovecii prophylaxis at 4 weeks of
age and continue until HIV infection has been excluded.
Co-trimoxazole is the first-choice drug unless contra-
indicated. Co-trimoxazole has not previously been recom-
mended before the age of 4 weeks because of the theoretical
risk of kernicterus with sulphonamide administration in
neonates. Hard evidence for this is lacking [27] and it is
unclear what the relative risks of this are compared with the
risks of P. jirovecii infection in young infants in whom the
diagnosis of HIV infection is made before 4 weeks of age.
Children aged 1 to 4 years should receive prophylaxis
against P. jirovecii if they have a CD4 count below 500
cells/μL or 15% of total lymphocyte count. Children aged 5
years and above should receive prophylaxis against
P. jirovecii if they have a CD4 count below 200 cells/μl or
15%, and it should be considered when they are approach-
ing these thresholds [28,29]. While intermittent dosing (3
days a week) is sufficient for P. jirovecii prophylaxis, daily
co-trimoxazole prophylaxis according to weight bands, as
in the current WHO guidelines [6], simplifies recommen-
dations with the additional benefit of protecting against
bacterial infections. This option is also therefore endorsed
by these guidelines. Daily co-trimoxazole prophylaxis may
also be considered for children travelling to countries with
a high prevalence of bacterial infections and/or malaria,
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irrespective of their CD4 count/percentage and current
treatment status [6,24,30,31]. The use of co-trimoxazole in
this context may also have additional benefit as antima-
larial prophylaxis [32], although specific malaria prophy-
laxis appropriate to the regions being visited should always
be prescribed.
Once ART has been started and the CD4 count has risen,
the risk of P. jirovecii infection decreases [33,34]. Most
paediatricians stop co-trimoxazole in children over 1 year
of age living in well-resourced settings 6 months after CD4
count recovery. The AntiRetroviral Research for Watoto
(ARROW) trial has reported additional benefits of continu-
ing co-trimoxazole prophylaxis after immune reconstitu-
tion in children in resource-poor settings. It is likely that
these additional benefits are related to antibacterial, anti-
malarial and anti-inflammatory effects. The findings of
this trial are therefore less likely to be of relevance in most
European settings [30].
Prophylaxis against other infections has been suggested for
those with very low CD4 counts. There is insufficient evidence
to make any recommendations for routine primary prophy-
laxis, but specific guidance is available [35]. Prophylaxis
against TB can be considered for children visiting countries
highly endemic for TB (see Section 10 below). The most
important means to reduce susceptibility to all opportunistic
infections is prompt initiation of ART when indicated.
5. When to start ART
ART is recommended:
• in all children under 1 year of age;
• in all children with significant disease (WHO stage 3 or
4 or CDC stage B or C);
• in asymptomatic children over 1 year of age based on
age-specific CD4 count thresholds;
• to be initiated before the CD4 count reaches the CD4
treatment threshold;
• in those with HCV or active TB coinfection.
ART should be considered:
• in asymptomatic children over 5 years of age at CD4
counts of 350–500 cells/μl, to potentially optimize CD4
count in adulthood;
• in children with high VL (> 100 000 copies/ml);
• in asymptomatic children aged 1–3 years irrespective of
immune status and VL;
• in sexually active adolescents, to minimize the risk of
onward transmission;
• in the presence of any significant HIV-related clinical
symptoms;
• in HBV coinfection irrespective of immune status.
5.1 Children under 1 year of age
ART should be started as soon as possible in all HIV-
infected children under 1 year of age irrespective of clinical
or immunological status [4,6]. Evidence for this comes
from the South African randomized controlled Children
with HIV Early Antiretroviral Therapy (CHER) trial [36,37],
which showed a 4-fold reduction in mortality among
asymptomatic infants starting ART before 3 months of age
compared with those starting at a CD4 percentage < 25% or
WHO stage 3 or 4. In addition, in Europe, a 4-fold reduc-
tion in HIV progression/mortality was observed among
infants starting ART at less than 3 months of age compared
with later in a large infant cohort meta-analysis [European
Infant Collaboration (EIC)] [38].
Additional CHER trial substudies have added further
evidence of the clinical [23,39], immunological [40] and
neurodevelopmental [41] benefits of early ART initiation in
infants. Data from European cohorts have also shown that
virological, clinical and immunological benefits from early
treatment are sustainable outside the trial setting [42,43].
Further analysis of laboratory parameters from the EIC has
demonstrated an association between early infant ART,
more rapid control of viraemia and a higher CD4 count up
until 12 months of age [44].
Universal treatment of all infants with HIV infection,
although challenging, is an achievable goal. The risks of
drug resistance and early toxicity are markedly outweighed
by improvements in short-term mortality and disease
progression, especially prevention of irreversible HIV
encephalopathy.
Infants should be reviewed at a minimum of monthly
intervals up to 6months of age in order to increaseART dosing
in line with growth. Symptomatic infants presenting with
severe illness (including opportunistic infections) should start
ART as soon as possible. Debate remains about whether ART
should be started immediately or deferred until treatment for
the presenting illness has started and the child is clinically
stable. There is no evidence to inform this, and it is recom-
mended that ART be started as soon as the child is stable
(ideally within 2 weeks of diagnosis). Expert pharmacist
advice should be obtained if there is a complex treatment for
a coinfection (e.g. TB) as drug interactions may interfere with
effectiveness and/or cause side effects. See Section 10 below
for further specific information on coinfection.
5.2 Children over 1 year of age – general principles
Starting ART is recommended in all children over 1 year of
age with HIV-related symptoms, and in asymptomatic
children with CD4 counts or percentages below or
approaching recommended age-related thresholds. Starting
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ART should also be considered in those with a high HIV
RNA VL (> 100 000 copies/ml), as they are more likely to
progress rapidly to symptoms or have a rapid fall in CD4
values [45–47].
The evidence for clinical benefit of ART in children with
AIDS/CDC category C disease is so strong that parental
refusal to treat is a child protection issue. CDC clinical
category B covers a wide range of disease severity. A
retrospective study from the USA demonstrating a signifi-
cant reduction in rate of progression of disease adds further
weight to the recommendation that children with category
B or C disease should be treated irrespective of their CD4
count/percentage [48]. PENTA now recommends that treat-
ment should be initiated for all children in WHO stage 3 or
4 (CDC category B or C) and considered in all children with
HIV-related symptoms (WHO stage 2; CDC category A).
CD4-guided treatment thresholds in asymptomatic chil-
dren are based predominantly on analysis of paediatric
and adult cohort data and extrapolation from the adult
Simple Trial Comparing Two Strategies for Management of
Anti-Retroviral Therapy (SMART study) [47,49–52]. Only
one randomized trial [Pediatric Randomised Early versus
Deferred Initiation in Cambodia and Thailand (PREDICT)]
has addressed the question of when to start ART in children
over 1 year of age. Thai children aged 1–12 years (median
age 6.4 years), with CD4 percentage 15–24%, were
randomized to start immediate ART or defer ART until the
CD4 percentage dropped below 15%. Rates of progression
and death were unexpectedly low in both groups during
144 weeks of follow-up. As a result, the study was under-
powered to detect a difference in the primary endpoint of
AIDS-free survival. Analysis of secondary endpoints did,
however, demonstrate better height-for-age Z scores in the
immediate treatment group [53].
The evidence for absolute age-related CD4 thresholds for
starting ART remains as for the PENTA 2009 guidelines, as
follows.
(1) Analysis of adult data
Data from the SMART trial clearly showed that adults
with CD4 counts between 250 and 350 cells/μL have
significantly better outcomes on ART than off ART
[51]. Adult (US and European) guidelines strongly rec-
ommend ART initiation at CD4 cell counts below 350
cells/μl [2,3,5,6].
(2) Comparison of child and adult data
Comparison of the short-term risks of disease progression
in pre-ART adult seroconverters in the Concerted Action
on SeroConversion to AIDS and Death in Europe
(CASCADE) cohort collaboration and in children aged 5
years and older in the paediatric HIV Paediatric Prognostic
Markers Collaborative Study (HPPMCS) cohort showed
that the short-term risk of disease progression was very
similar in young adults (around 20 years old) and children
aged 5 years and older [52]. Absolute CD4 count, rather
than percentage, should therefore be used to determine
treatment thresholds in children from the age of 5 years.
These should follow the same CD4 threshold recommen-
dations for treatment recommended in adult guidelines.
(3) Analyses of child data
Analyses from the HPPMCS cohort demonstrated that
CD4 counts are highly prognostic of disease progression
at all ages after infancy [49]. However, to obtain a
uniform progression risk with the thresholds for adults
and children aged 5 years and over, thresholds between
1 and 5 years of age would have to change approxi-
mately every 6 months or less. This would require too
many age bands for a workable guideline, and the
historical data on which progression risks are based
are not robust enough to warrant ignoring the impor-
tance of practical guidance and the desirability of
general concordance with other international guide-
lines. Therefore, only two age bands between 1 and 5
years have been selected. CD4 count as well as CD4
percentage thresholds should be taken into account. In
the HPPMCS data, 10–20% of CD4 percentages and CD4
counts are discordant in terms of ART initiation thresh-
olds adopted for these PENTA guidelines. However, these
values are frequently concordant on a subsequent blood
sample. If consistent discordance is observed, and par-
ticularly if the count is below the threshold although the
percentage is not, then initiation of ART is strongly
recommended [54].
The prognostic significance of plasma HIV RNA for short-
term risk of disease progression is much weaker than CD4
count or percentage [45–47,50]. However, ART is recom-
mended in asymptomatic children with VL persistently
above 100 000 copies/ml, even if they do not meet CD4
count criteria.
Rapid clinical, virological or immunological failure may
occur, but, in general, ART does not need to be started
quickly except in infants or in an older child seriously ill
with advanced HIV disease. Time spent preparing and edu-
cating the family, particularly about adherence, is very
important. Starting ART needs to be supported and pro-
moted by the caregivers if it is to succeed. It is preferable
not to start ART at the first clinic visit. Older children
should preferably know why they are taking treatment, and
timing of full or partial naming of HIV diagnosis in relation
to starting ART is an important consideration. These CD4
thresholds are for children without coinfection. See Section
10 for guidance in the context of HBV/HCV, TB and oppor-
tunistic infections.
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5.3 Children aged 1–3 years
As in the previous PENTA guidelines [1], CD4 thresholds
for absolute indication to start treatment outside the infant
period are based on data extrapolated from adults and
analysis of HPPMCS data. The age bands (1−< 3, 3−< 5 and
≥ 5 years) provide harmony with DHHS guidelines (which
are also largely based on HPPMCS data) [4] but contrast
with new WHO guidelines which group all children aged
1–5 years together. The PENTA 2009 guidelines defined
thresholds based on an individual child’s risk of progres-
sion to AIDS or death over the subsequent 1 year (derived
from HPPMCS data using the on-line PENTA calculator
available at http://www.hppmcs.org/). The absolute treat-
ment thresholds aimed to maintain the overall risk of
mortality below 2% and the AIDS progression risk below
5% (acknowledging that progression risk is higher and
more variable in the first few years after infancy). The
ongoing success of ART means that we should continue to
expect better clinical outcomes for children, and in 2015
these rates of disease progression are no longer deemed
acceptable. Looking more closely at the calculated risks,
using a threshold of < 1000 cells/μl and < 25%, between
1 and 3 years, risk of progression at these thresholds
increases dramatically at younger ages (Table 2). For these
reasons, while we recommend keeping the 2009 CD4
thresholds in this age range, it is also recommended that
ART should be considered in all children aged 1–3 years
in order to minimize risk of progression and death and
to minimize potential deleterious effects of ongoing viral
replication on the child’s rapidly developing brain and
immune system.
5.4 Children aged 3–5 years
As mentioned above, the levels of risk deemed acceptable
in previous versions of the PENTA guidelines (2% mor-
tality and 5% AIDS) should be lowered in the light of
the ongoing success of ART, and the absolute CD4
threshold for ART initiation in children aged 3–5 years
has been increased to 750 cells/μl and 25% accordingly
(Table 3). This is in line with current US and WHO guid-
ance [4,6].
5.5 Children aged > 5 years
For older children, the recommended absolute threshold for
ART initiation remains at a CD4 count of 350 cells/μl, in
line with current European adult guidelines [2,3]. However,
ART should be considered below 500 cells/μl, in line with
current US and WHO guidelines, in order to potentially
optimize ultimate CD4 count in adulthood (see below).
Treatment should certainly be initiated before the CD4
count reaches 350 cells/μl rather than letting it fall below
this value. The ongoing Strategic Timing of Antiretroviral
Treatment (START) trial comparing ART initiation at > 500
cells/μl versus < 350 cells/μl will report in 2016.
5.6 Other indications for ART initiation irrespective of
immunological or virological status
• Coinfection with HCV or TB
• Autoimmune manifestations (e.g. thrombocytopenia)
• Malignancy
• Growth or puberty delay
• Neurocognitive delay
• Prevention of transmission in sexually active adolescents
• Pregnancy
• Primary infection (e.g. after nosocomial or sexual
transmission)
• Child and family wish to start treatment (following full
discussion of risk/benefit)
Table 2 Percentage risk of progression to AIDS or death in the next
12 months associated with absolute thresholds at age 1–3 years
AIDS Death
CD4 = 25%
CD4 = 1000
cells/μL CD4 = 25%
CD4 = 1000
cells/μL
1 year (%) 16 23 4.5 6.6
2 years (%) 8.8 9.4 2 1.7
3 years (%) 6 5.1 1.2 0.6
Table 3 Percentage risk progression to AIDS or death in the next
12 months associated with absolute thresholds at age 3–5 years at (a)
previous thresholds and (b) updated thresholds
(a)
AIDS Death
CD4 = 20%
CD4 = 500
cells/μL CD4 = 20%
CD4 = 500
cells/μL
3 years (%) 8.1 8.1 1.8 1.5
4 years (%) 6 3.7 1.2 0.4
5 years (%) 4.7 3.5 0.9 0.3
(b)
AIDS Death
CD4 = 25%
CD4 = 750
cells/μL CD4 = 25%
CD4 = 750
cells/μL
3 years (%) 6 5.6 1.2 0.7
4 years (%) 4.5 3.5 0.8 0.3
5 years (%) 3.6 3.4 0.6 0.3
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5.7 Consideration for starting antiretroviral therapy to
optimize immune function in adulthood
The aimof treatment in paediatric HIV infection should extend
beyond survival to maximizing long-term outcomes and
quality of life. Current treatment goals should thus include
normal growth and physical, pubertal, neurological and
psychological development and immune reconstitution, while
minimizing long-term drug toxicity and viral drug resistance.
To date, studies with such long-term outcome data have been
lacking, but in the field of immune reconstitution, mathemati-
cal models may allow us to begin to use predicted long-term
outcomes for treatment initiation decisions.
A number of studies indicate that, even with good adher-
ence, long-term immunity may remain suboptimal after
starting ART. The reasons for this are likely to be multi-
factorial and include: a depleted/inadequate immunologi-
cal memory for childhood infections and vaccinations;
destruction/skewing of B- and T-cell repertoires; and
persistently low CD4 counts in relation to healthy age-
matched children (reviewed in [55]). Mathematical model-
ling of data from large European and African cohorts
indicates that CD4 cell recovery depends strongly on both
the age and CD4 count at ART initiation [56,57]. The
important predictions from these studies are as follows.
1) Children under 5 years of age have very good potential
for recovering their CD4 counts, even when counts are
low at ART initiation.
2) In contrast, with every year that passes after the age of
5 years, the potential for long-term CD4 count recovery
to the normal range diminishes (Fig. 1).
Current PENTA guidelines recommended a uniform
threshold for children over 5 years old and continuing at
the same threshold through adulthood (CD4 count < 350
cells/μl). These mathematical projections raise the concern
that this approach may substantially compromise long-
term CD4 recovery in adulthood, particularly for children
older than 10 years at ART initiation. The reasons for the
effects of age and initial CD4 count on immune reconsti-
tution are only partially understood. They are likely to be
attributable to a combination of declining thymic output
from its peak at 1 year of age and irreversible immune
injury. Whatever the causes, it would appear logical to
strive to initiate ART at combinations of age and CD4
counts that are most likely to achieve a better long-term
reconstitution.
The absolute thresholds for ART initiation represent the
lowest CD4 thresholds for ART initiation to prevent disease
progression; however, these may not be optimal thresholds
for CD4 recovery in adulthood. Although Figure 1 repre-
sents extrapolations in time and from available data, it can
be used as a guide to help indicate how delay in ART
initiation may adversely influence eventual CD4 recovery.
With current treatment regimens, which are less toxic and
easier to take, there is a theoretical case for starting ART at
any CD4 count in older children, especially those over 5
years old.
Another long-term consideration when starting ART in
children, irrespective of CD4 count, is the possible benefit
of minimizing HIV viral reservoirs in order to optimize the
potential for achieving eventual ‘functional HIV cure’.
Recent reports in both adults and children have indicated
2
1000
750
500
350
250
4 6 8 10
Age at ART initiation (years)
CD
4 
co
un
t a
t A
RT
 in
itia
tio
n 
(ce
lls
/µL
)
Lo
ng
-te
rm
 e
xp
ec
te
d 
CD
4 
co
un
t (c
ell
s/µ
L)
12 14
1000
900
800
700
600
500
Fig. 1 Predicted long-term CD4 count following antiretroviral therapy (ART) initiation at thresholds of 250, 350, 500, 750 and 1000 cells/μL (curves),
using models derived from the AntiRetroviral Research for Watoto (ARROW) study. Delaying treatment in children younger than 5 years (to the left
of the vertical line) results in relatively small differences in long-term expected CD4 count. In contrast, children aged over 5 years (right of the vertical
line) are predicted to experience a steady deterioration in long-term CD4 count as ART is initiated at increasingly older ages (and a constant CD4
threshold). Dashed lines show that a 6-year-old delaying treatment until the age of 13 years, with a CD4 count of 350 cells/μL throughout, may
expect the long-term CD4 count to be lowered by 151 cells/μL: from 770 to 619 cells/μL.
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that early and sustained full suppression of HIV may limit
viral reservoirs [58,59] and that a longer cumulative time
spent with ongoing viral replication is associated with a
larger viral reservoir [60]. How this may relate to future
‘cure’ is yet to be determined, but it should also be borne in
mind when considering ART initiation in young children
who may see the advent of new curative treatments within
their lifetime.
We therefore recommend that the CD4 thresholds indi-
cate the lowest limits below which a child should not be
allowed to fall before starting treatment. Where resources
allow and families are motivated, discussions should be
had with children, young people and their families about
the option of starting treatment at higher CD4 counts with
the aim of optimizing long-term immune recovery, while
always balancing possible long-term toxicity effects of
ART and the potential for viral drug resistance if adherence
is poor. With an increase in the number of indications for
ART, and in the context of less robust evidence for clinical
benefit, optimal adherence is essential so as not to com-
promise future treatment options though development of
resistance to first-line drugs.
5.8 Comparison of PENTA guidelines with DHHS and
WHO guidelines for HIV-infected children and adults
As can be seen from Table 1, PENTA and US guidelines are
generally in agreement; however, DHHS guidelines advise
that ART initiation should be considered for any child
irrespective of immune and clinical status. Furthermore,
the CD4 thresholds are higher for children over 5 years of
age. This is in line with recent updates to adult DHHS and
WHO guidelines, which give a universal ART threshold of
500 cells/μl, while DHSS recommend that asymptomatic
adults should be considered for treatment at any CD4
count. The latter is in part based on cohort data demon-
strating a possible benefit with respect to non-AIDS-related
morbidity for all patients on ART as well as a known
decrease in the risk of onward sexual transmission (sum-
marized in [5]).
These most recent changes to the adult US guidelines
have been debated extensively; the strength of the evi-
dence on which they are based is relatively weak [7,61,62].
It is the opinion of PENTA that extrapolation of these
adult data to guide treatment for children is inadvisable
at present. Results of large randomized trials comparing
higher versus lower treatment thresholds in adults
are expected in 2016 [http://clinicaltrials.gov/show/
NCT00867048 (START); http://clinicaltrials.gov/show/
NCT00495651 (TEMPRANO)]. This evidence will clarify the
wider risks and benefits of starting treatment at higher CD4
counts.
Current European/UK adult guidelines are more con-
servative [2,3]. The absolute CD4 threshold for ART initia-
tion remains at 350 cells/μl, with a number of exceptions
where starting at higher thresholds is indicated (end
organ involvement, hepatitis/TB coinfection, pregnancy,
discordant couples or primary infection). The PENTA 2015
guidelines are in line with European adult guidance,
with the additional option that, for older children, ART
initiation at CD4 counts > 350 cells/μl, to optimize
immune reconstitution/CD4 count in adulthood, should be
considered.
WHO guidelines have harmonized and simplified adult
and child recommendations as far as possible, recommend-
ing starting ART in all children under 5 years of age, and
in older children with CD4 counts < 500 cells/μl. Treatment
is recommended for all children under 5 years old for
mainly programmatic reasons alongside extrapolation of
data from adult cohort studies suggesting clinical benefit to
treating irrespective of immune status, while accepting that
neither data from PREDICT [53] nor data from a causal
modelling study from a large paediatric cohort study [63]
indicate clinical benefit. It is suggested that, by simplifying
guidance and making treatment universal, access to ART
for children will increase in resource-poor settings where it
remains inadequate. This is fortunately not as relevant for
the majority of European countries, so for this reason
universal treatment is still only recommended by PENTA
for those under 1 year of age, for whom the evidence-based
health benefits are incontrovertible.
6. Which ART regimen to start as
first-line therapy
• Children should start effective (at least three drugs) ART,
usually a dual or triple NRTI backbone together with
either a ritonavir-boosted PI or an NNRTI.
• Children exposed to NVP during failed PMTCT (or in
whom perinatal NVP exposure cannot be excluded)
should be started on a boosted PI-containing regimen,
as transmitted resistance may lead to failure of NVP-
containing ART.
• Children aged < 3 years not exposed to NVP during
failed PMTCT may be initiated on either NVP or
ritonavir-boosted lopinavir (LPV/r)-containing ART. We
recommend that NVP should be given together with
three NRTIs (ABC, 3TC and ZDV) in all infants and in
children aged 1–3 years with VL > 100 000 copies/ml or
signs of CNS involvement as an induction-maintenance
strategy, unless any of these drugs are contraindicated
(such as ABC in HLA B*5701-positive children).
• In children aged > 3 years, either NNRTI or boosted
PI-based ART is acceptable for initial therapy. Factors
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such as availability of age-appropriate formulations,
palatability, dosing frequency and adherence should be
considered when choosing NNRTIs or boosted PIs.
• The preferred NNRTI is NVP in children aged < 3 years not
exposed to NVP during failed PMTCT, and EFV in children
aged > 3 years. The preferred PI in children aged < 6 years
is LPV/r, in children aged 6−12 years it is ATV/r, and in
children aged > 12 years it is ATV/r or DRV/r.
• INSTI- based ART may be an alternative regimen in
children over age 12 years.
• The preferred first-line NRTIs are ABC/3TC in
children aged < 12 years and TDF/FTC or ABC/3TC (if
VL < 100 000 copies/ml) in children aged > 12 years.
• Age, HLA B*5701 genotype, previous drug exposure,
resistance profile, coinfections, available formulations
and likely adherence should be taken into account when
choosing a first-line regimen.
• See Table 4 for details of recommended first-line ART
regimens.
6.1 General principles of treatment
To achieve long-term virological suppression requires high
levels of ART adherence. Children’s doses should be
checked for age and weight or surface area at each visit,
and this should be done frequently during periods of rapid
growth, especially infancy. Doses should be rounded up
(not down) to convenient syrup volumes or tablet formu-
lations, and parents should be given careful instructions on
dosage, timing, administration, repeating doses if there
is vomiting within 1 hour after taking medication, and
seeking medical attention rather than discontinuing if
drugs are refused or side effects are suspected. Supervised
initiation of therapy in hospital or at home with visiting
nurses may be appropriate for some children and families,
particularly newly diagnosed infants. When drugs show
comparable toxicity and efficacy profiles, clinicians should
be aware of pricing, drug availability and national policies.
The standard first-line treatment regimen remains two
NRTIs with either an NNRTI or a boosted PI (see Table 4).
Although transmitted viral resistance remains rare in
children, it may lead to suboptimal response to the first-
line treatment [19]. Therefore, pretreatment resistance
genotyping should be performed.
6.2 NNRTI or boosted PI for first-line ART?
Boosted PIs have a higher barrier to viral resistance, but
have more potential drug interactions and cause higher
rates of dyslipidaemia, while NNRTIs are often more pal-
atable although virological failure frequently results in
whole-class resistance. Recent studies have produced dis-
cordant results on whether or not NNRTI- and boosted
PI-based regimens are equally effective, especially in the
youngest children. This discordance has resulted in con-
flicting recommendations for first-line drug regimens and
merits consideration.
6.2.1 Infants and young children (< 3 years old)
Infected infants exposed to NVP during failed PMTCT (or in
whom perinatal NVP exposure cannot be excluded) should
be started on a boosted PI-containing regimen, as transmit-
ted resistance may lead to failure of NVP-containing ART
[64,65]. LPV/r should not be administered to premature
Table 4 Recommended first-line antiretroviral therapy (not in the context of hepatitis B virus or tuberculosis coinfection)
< 1 year 1–3 years 3–6 years 6–12 years > 12 years
Preferred Third agent LPV/r
NVP
LPV/r
NVP
LPV/r
EFV
ATV/r
EFV
ATV/r
DRV/r
EFV
Backbone ABC*/3TC (+ ZDV if NVP)‡ ABC*/3TC (+ ZDV if NVP and
CNS involvement or high VL)†
ABC*/3TC ABC*/3TC TDF/FTC§
ABC*/3TC (if VL < 105 copies/mL)
Alternative Third agent – – NVP
DRV/r
NVP
LPV/r
DRV/r
NVP
LPV/r
RAL**
DTG
Backbone ZDV¶/3TC ZDV¶/3TC ZDV¶/3TC
TDF/3TC (FTC)
ZDV¶/3TC
TDF/3TC (FTC)
ABC*/3TC
3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; CNS, central nervous system; DRV/r, ritonavir-boosted darunavir; DTG, dolutegravir; EFV,
efavirenz; FTC, emtricitabine; LPV, lopinavir; NVP, nevirapine; RAL, raltegravir; TDF, tenofovir; VL, viral load; ZDV, zidovudine.
*Prior to starting abacavir (ABC), patients should be tested for human leucocyte antigen (HLA) B*5701. If positive, then ABC should not be prescribed. †In
children < 3 years, consider adding zidovudine (ZDV) to nevirapine (NVP)-based regimens if there is a very high viral load (VL) or central nervous system (CNS)
involvement until VL has been suppressed for at least 3 months. ‡Four-drug induction for infants on NVP-based therapy may be considered until VL has been
suppressed for at least 3 months, followed by three-drug maintenance therapy. §Tenofovir (TDF)/emtricitabine (FTC) is preferred in older children with
VL > 100 000 copies/ml. Some clinicians would advocate deferring the use of TDF until after puberty. ¶ZDV should be avoided if possible, apart from the
indications described in the above notes. **In rare instances (e.g. transmitted resistance or toxicity), raltegravir (RAL) may be used as first-line therapy in
children < 12 years of age.
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neonates or to term neonates below 2 weeks of postnatal age
because of the increased risk of toxicities reported in prema-
ture and very young babies [66,67].
International Maternal Pediatric Adolescent AIDS Clinical
Trials (IMPAACT) P1060 suggested better efficacy for LPV/r
than for NVP in children aged below 3 years, even without
prior NVP exposure. Children randomized to an NVP-
containing regimen were twice as likely as those on an LPV/
r-based regimen to reach a composite endpoint of: virological
failure, treatment discontinuation or death at 24 weeks of
follow-up (40.8% versus 19.3%, respectively; P < 0.001) [68].
Transmitted NVP resistance, emergence of NVP resistance
because of high VL in infancy and possible low NVP levels
during lead-in dosing [69] may have played a role. A compo-
site endpoint at only 24 weeks, and the low-income setting,
make it difficult to extrapolate the results in terms of longer
outcomes and generalizability to higher income settings.
In contrast, PENTA 9/ Pediatric AIDS Clinical Trials Group
(PACTG) 390 (PENPACT-1), a randomized trial conducted in
resource-rich settings, showed no difference between first-
line NNRTI – and boosted PI-based regimens in virological
outcomes in children aged 0.1–17.8 years (median age 6.5
years) [70]. An underpowered subanalysis by individual
drug in children younger than 3 years of age found no
difference in virological outcome between children on NVP-
and LPV/r-containing ART regimens (G. Tudor-Williams,
unpublished results). In agreement with PENPACT-1, the
Prevention of Malaria and HIV Disease in Tororo, Uganda
(PROMOTE) study, a small open-label RCT in Uganda of
children aged 0.4–5.9 (median 3.1) years not exposed to
NVP, showed comparable results at 48 weeks in terms of
virological suppression, CD4 gain and severe adverse events
for NNRTI- and LPV/r-containing ART regimens [71].
The European Pregnancy and Paediatric HIV Cohort Col-
laboration (EPPICC) study, of children under 1 year of age
commencing ART at a median age of 3.6 months, showed no
difference in virological suppression or CD4 response
between children receiving NNRTI-based ART (mostly NVP)
and those receiving LPV/r-based ART over a median of 5.9
years of follow-up. The power to detect small differences
was low as comparatively few infants started boosted
PI-based ART. However, in this cohort study, children on an
NNRTI-based four-drug regimen (NNRTI + 3 NRTIs) had
significantly better virological suppression and CD4 gain at
12 months after ART initiation when compared with either
PI- or NNRTI-based three-drug regimens [42]. The initial
rapid virological suppression and immune reconstitution on
an NVP-based four-drug regimen compared with a three-
drug regimen have been confirmed in ARROW, although
differences in virological/immunological outcomes were
not sustained following a switch to three-drug therapy at 36
weeks from ART initiation [72] (see Section 6.5).
The evaluation of virological outcomes in real-life clinical
settings in the national cohort of HIV-infected children in
the UK/Ireland [Collaborative HIV Paediatric Study (CHIPS)]
showed similar rates of VL suppression by 12 months for
different first-line regimens in children aged < 3 years (NVP
+ 2 NRTIs; NVP + 3 NRTIs; LPV/r + 2 NRTIs) [73]. However,
three-drug NVP-based regimens were associated with faster
progression to virological failure long term, while four-drug
NVP-based regimens had the lowest risk of failure.
In practice, the poor palatability of boosted LPV/r liquid
formulation precludes its use in many young children,
and NVP remains a first-line option in infants and young
children not exposed to NVP perinatally. NVP has good
palatability, high cerebrospinal fluid (CSF) penetration and
a favourable lipid profile. Taking the above into consid-
eration, either NVP- or LPV/r-containing ART may be
initiated in children younger than 3 years of age. However,
in view of the above-mentioned evidence and the fragility
of NVP at high VLs, we recommend that NVP should be
accompanied by three NRTIs, as an induction-maintenance
strategy, in infants and young children with VL > 100 000
copies/ml or signs of CNS involvement, including
neurodevelopmental delay (Table 4). Earlier viral suppres-
sion and greater early CD4 responses with the use of
four-drug induction with a triple NRTI backbone [42,71]
may have potential benefits in terms of reduced viral
reservoirs and reduced risk of CNS compartmentalization.
Early detection of treatment failure should be picked up by
regular monitoring of viral response in the first few months
following treatment initiation.
6.2.2 Children > 3 years of age
As mentioned above, PENPACT-1 found no difference in
clinical, virological or immunological outcomes between
NNRTI- and PI-based regimens [70]. The virological
outcome analysis in the CHIPS cohort study showed that in
children aged > 3 years overall virological suppression by
12 months was high (> 93%) and there was no difference
between NNRTI- and PI-based regimens. However, the pro-
gression to virological failure was different between regi-
mens: in the first 2 years on therapy, it was slowest for EFV
+ 2 NRTIs or NNRTI + 3 NRTIs and fastest for NVP + 2
NRTIs. After 2 years on therapy, the risk was similar for
EFV and NVP three-drug ART, and remained lowest for
NNRTI four-drug ART, although the number of children on
the latter regimen was small [73].
Either NNRTI- or boosted PI-containing regimens are
acceptable for initial therapy in children above 3 years of
age. Issues to consider when choosing an NNRTI or boosted
PI regimen include the availability of age-appropriate for-
mulations, palatability, dosing frequency and adherence.
For EFV and NVP, single point mutations in the reverse
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transcriptase gene rapidly lead to virological failure and
whole-class resistance. Families should be counselled care-
fully about these issues before starting ART. If predicted
adherence is questionable, as is often seen in teenagers, a
more forgiving PI-based regimen should be initiated with a
possibility of subsequent simplification to an NNRTI FDC
one-tablet-once-daily regimen when virological suppres-
sion is sustained and adherence is established.
6.3 Which NNRTI?
The choice for the first-line NNRTI-based therapy in chil-
dren is either EFV or NVP. Until recently, only NVP was
licensed for children < 3 years of age because of very poor
bioavailability of EFV syrup in this age group. The US Food
and Drug Administration (FDA) have recently approved EFV
capsule sprinkles for children as young as 3 months of age,
based only on the results of a paediatric pharmocokinetic
(PK) population model including three open-label paediatric
studies and a PK comparison study in adults [74,75]. Vari-
able EFV exposure in young children, as shown in a recent
study of EFV PK in children under 3 years old [76], and lack
of experience with EFV sprinkle formulation in children
may prevent its widespread use.While waiting for the results
of further studies, EFV sprinkles should only be considered
as an alternative regimen to NVP in this age group and PK
monitoring is currently recommended. Pharmacogenetics
may be a useful adjunct in the future as testing for
cytochrome P450 2B6 (CYP2B6) polymorphisms has been
shown to predict adequate dosing [76].
As seen in adult studies [77], two recent retrospective
paediatric cohort studies, in resource-limited and resource-
rich settings, comparing EFV and NVP showed that EFV
was associated with superior virological outcomes [78]
[73], although in the UK/Ireland CHIPS cohort, the benefit
of EFV-based regimens over NVP-based regimens in terms
of virological failure was very modest after 2 years of
therapy [73]. In the ARROW trial, a nonrandomized com-
parison of NNRTI- based regimens showed favourable
short-term VL suppression with EFV; however, long-term
suppression depended on age, and was better with EFV in
children aged < 10 years, and with NVP in those aged > 10
years [79]. A recent systematic review and meta-analysis
which included data on nearly 4000 children showed a
lower frequency of severe adverse events and treatment
discontinuations with EFV than NVP, although EFV use
was associated with higher rates of CNS adverse events
[80]. Overall, these data support the use of EFV as the
preferred NNRTI in children aged > 3 years. However,
for children with neurodevelopmental and psychiatric
comorbidities, NVP may be a better choice in view of
potential CNS side effects associated with EFV.
In summary, the preferred NNRTI is NVP in children
aged < 3 years, and EFV in children aged > 3 years.
6.4 Which boosted PI?
PI use in children should be ritonavir-boosted to optimize
efficacy. Consideration of which PI should be used is based
on balancing pill burden, toxicity, experience, available
paediatric data and available formulations for a given age
group.
LPV/r [Kaletra (AbbVie, North Chicago, IL, USA)] is the
only combined PI/ritonavir liquid or tablet formulation for
children and the only PI licensed for children aged < 3
years in Europe. It must be given twice daily [81]. ATV/r, a
once-daily PI, is licensed for children aged > 6 years in
Europe, and is the preferred boosted PI in this age group.
DRV/r is licensed for children aged > 3 years in the USA
(treatment-naïve and treatment-experienced) and Europe
(treatment-experienced aged > 3 years; treatment-naïve
> 12 years). Paediatric studies with once-daily administra-
tion of DRV/r have not been conducted in children aged
6–12 years. It is therefore recommended that DRV/r be used
twice daily in children aged < 12 years while awaiting new
data. In view of this, we recommend DRV/r as an alterna-
tive first-line PI in children in this age group (6–12 years),
especially when there is known transmitted PI resistance or
intolerance precluding use of other PIs. Both ATV/r and
DRV/r are acceptable first-choice PIs in older children (> 6
years old for ATV/r and > 12 years old for DRV/r) because
of their favourable virological outcomes and the availabil-
ity of once-daily treatment (Table 4). Fosamprenavir/r
(fAPV/r), a twice-daily PI, is licensed for children from age
6 years in Europe. Although fAPV/r is approved by the FDA
in children aged > 4 weeks, it is not recommended for
children aged < 6 months because of low drug exposure in
this age group [82]. In view of limited paediatric experi-
ence, the adverse effect on lipids, the twice-daily regimen
and meal requirements, it is not recommended for first-line
therapy in children.
Some PIs (ATV and fAPV) may be used unboosted in
special circumstances where ritonavir is not tolerated, but
this is not recommended because of reduced efficacy.
Where possible, doses of unboosted PIs should be moni-
tored by TDM.
In summary, the preferred PI for children less than 6
years old is LPV/r, for children 6–12 years old it is ATV/r,
and for children > 12 years old it is ATV/r or DRV/r
(Table 4).
6.5 Choice of NRTI backbone
Factors to consider when choosing the dual NRTI
combination:
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• the potential for resistance and cross-resistance (and
hence future therapy options);
• tolerability and toxicity;
• dosing frequency;
• age-appropriate formulations including FDCs.
3TC and ABC are the preferred first-line NRTIs in children
< 12 years of age. Superiority of ABC over ZDV has previ-
ously been reported in children [83]. Starting with ABC and
3TC also has the advantage of preserving (and even increas-
ing) susceptibility to ZDV for future options in cases of
virological failure, whereas starting on ZDV may lead to
accumulation of thymidine analogue-associated mutations
(TAMs) affecting subsequent susceptibility to ABC [84,85].
Both ABC and 3TC can be given once daily to children
over 3 months old, which is supported by PK data in PENTA
13 and PENTA 15, and virological outcomes in ARROW
[71,86–88]. 3TC and ABC both have palatable liquid formu-
lations, and scored breakable tablets have recently become
available. Children over 30 kg can be given the adult fixed
dose combined pill [Kivexa (ViiV Healthcare, Middlesex,
UK)]. As a consequence of inferior 96-week virological
efficacy of ABC/3TC compared with TDF/FTC in adults with
VL ≥ 100 000 copies/ml [2], an ABC/3TC backbone is rec-
ommended as an alternative rather than the preferred back-
bone in older children with very high VLs (Table 4).
ZDV is recommended as a substitute for ABC in children
with the HLA genotype B*5701, as they have an increased
risk of severe hypersensitivity reactions to ABC. ZDV is
also recommended alongside ABC and 3TC in infants and
in young children with high VLs receiving NVP (see
Section 6.3 above). It should be given twice daily. It is not
recommended as first-line treatment in other situations,
but remains an important component of neonatal PEP.
TDF has been licensed for children aged > 2 years by the
FDA and European Medicines Agency (EMA); however, the
long-term risk of renal and bone toxicity remains a possible
concern (see Section 9 on drug toxicity). As a result of limited
long-term safety data in young children and unresolved
concerns over the effects on bone and kidneys with prolonged
use, TDF is recommended as a preferred first-line NRTI only in
older children (aged > 12 years or weight > 35 kg) with no
underlying renal insufficiency or other risk factors signifi-
cantly affecting bone and renal health. Some clinicians prefer
towait until after puberty because of uncertain effects on bone
health (Table 4). TDF is also recommended as a first-line NRTI
in all children aged > 2 years with HBV coinfection (see
Section 10 on coinfections). It is available in co-formulated
tablets with FTC as mentioned above.
FTC is chemically very similar to 3TC and they are inter-
changeable. FTC has been co-formulated with TDF [Truvada
(Gilead, Forest City, CA, USA)] and TDF and EFV (Atripla,
Bristol-Myers Squibb, New York, NY, USA and Gilead), which
may be used in older children (see below). It is also included
with TDF in the more recently developed FDCs based on the
second-generation NNRTI rilpivirine (RPV) [Eviplera (Gilead
and Janssen Therapeutics, Titusville, NJ, USA)] and the INSTI
elvitegravir (EVG) [Stribild (Gilead)].
Where possible, once-daily and fixed dose formulations
should be used to reduce pill burden and potentially
improve adherence.
In view of well-documented toxicities, stavudine (d4T) is
no longer recommended for treatment of HIV-infected chil-
dren in Europe. However, its efficacy is acknowledged and it
is accepted that, in rare circumstances, it may be the only
option available.Didanosine (ddI) is no longer recommended
for first-line therapy because of the high risk of toxicities and
the availability of safer options (see Section 9 on toxicity).
Children arriving in Europe from other regions on d4T or ddI
should be changed to another regimen if possible.
6.6 NRTI-only regimens
Triple NRTI therapy has been shown to have inferior viro-
logical and immunological outcomes and a high risk of
selection for resistance mutations in ART-naïve adult
patients [89]. The ARROW study showed that children on a
three-NRTI maintenance regimen with 3TC, ABC and ZDV
had inferior virological outcomes at week 144 and more
ZDV-related neutropenia, but no difference in disease pro-
gression or immunological outcomes when compared to
NNRTI plus 3TC and ABC [71]. Based on these data, triple-
NRTI regimens are not recommended except in special
circumstances when significant drug interactions or toxic-
ity risks prevent the use of NNRTI- or PI-containing ART
(e.g. for concomitant TB treatment; see Section 10 below).
6.7 Integrase inhibitors (INSTIs)
RAL, a twice-daily INSTI, in combination with two NRTIs
is now a first-line options for adults [2,5] and is licensed
for treatment-experienced children from 4 weeks of
age. Dolutegravir (DTG), a second-generation INSTI, has
recently been licensed for treatment-naïve adults and chil-
dren > 12 years of age. An international paediatric trial of
its use in ART-naïve and -experienced children is planned
(the PENTA 20 trial). EVG, a once-daily INSTI, requires
boosting with ritonavir or cobicistat. It is a component of
the FDC Stribild and is now recommended as another
preferred regimen for ART-naïve adult patients in the USA
and Europe [2,5].
Given the evidence on the efficacy and safety of RAL
and DTG derived from studies of treatment-naïve adults
and treatment-experienced children [90,91], RAL- and
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DTG-containing regimens can now be recommended as
alternative first-line ART in children older than 12 years. In
children younger than 12 years, there are no data on the
use of either drug in treatment-naïve children. Their first-
line use should therefore be restricted to specific circum-
stances (transmitted resistance and intolerance).
7. Adherence and HIV knowledge
• Adherence to treatment is paramount and should be
discussed at each clinic visit.
• Every effort should be made to simplify a regimen to
support adherence (e.g. using once-daily regimens, FDCs
and ‘forgiving’ regimens with higher barriers to resist-
ance). Simple adherence aids should be used when
appropriate.
• Children should know of their HIV diagnosis before
adolescence.
• Monitoring for psychological, neurocognitive and
mental health issues should be routine, allowing early
supportive and therapeutic intervention.
Optimal adherence to treatment is of paramount impor-
tance for long-term efficacy of ART, and younger children
rely on caregivers to deliver this. Although there are some
data on the barriers to and predictors of adherence [92],
there are few studies of successful interventions to improve
it [93,94], and there is no gold standard for measuring it.
Adherence can be influenced by many factors, including
those related to the child/young person (e.g. developmental
stage, treatment fatigue and knowledge of status), family
and caregivers (e.g. relationship to the child, responsibility
for adherence and caregiver beliefs), the antiretroviral
regimen (e.g. convenience, palatability, formulation and
toxicity), culture and society [95,96]. Some of these factors
are outside the control of the treating clinician, but should
be acknowledged and addressed. Factors that can be influ-
enced by the medical team include once-daily medication
regimens, side effects, choice of formulation and route of
administration (e.g. oral versus gastrostomy). A recent
meta-analysis of RCTs in adults has highlighted that once-
daily regimens and lower pill burden are associated with
better adherence, the latter also being associated with
better virological suppression [97].
Despite the difficulties and a lack of easy solutions,
the issue of adherence should always be addressed
nonjudgementally, both before and after starting children
on ART. It is acknowledged that adherence issues change
with age and that adherence may be particularly difficult in
adolescence [98]. Despite every effort to support adherence,
some HIV-infected children and young people may have
difficulty with taking medications, leading to detectable VL
and associated risk of poor health status, development of
drug resistance and risk of onward transmission in sexually
active adolescents. In these individuals, careful considera-
tion should be given to options such as a switch to a
regimen with a higher barrier to resistance, or even treat-
ment interruption alongside ongoing education regarding
HIV transmission.
Every effort should be made to simplify adherence to
treatment for children and caregivers. Simple aids to
adherence should be used where appropriate – including
adherence apps, dossette boxes, pill diaries, text messages
and phone alarms. The following adherence points should
be considered before prescribing a child’s antiretroviral
regimen.
• Is there a once-daily regimen?
• What is the most forgiving regimen in terms of:
• timing? (Can a dose be missed or late from time to
time? Does administration need to be timed with food
intake? What timing best suits the family’s routine?)
• pill count? (Is an FDC available?)
• barrier to resistance? (Should a boosted PI backbone
be used?)
• Are the parents on treatment, and could the same
regimen be used for the child?
• What are the possible side effects of the regimen – might
they reduce adherence (e.g. jaundice with ATV)?
• Who is taking responsibility for adherence support –
within the family and the medical team?
• How is adherence going to be measured (VL, drug levels,
pill counts etc.)?
Before a child or young person goes home from the clinic
with their new medication, an adherence support plan
should be in place, with contact numbers, a review sched-
ule, peer support plan etc. Families should be encouraged
to call the clinic team if there are problems, rather than
struggle unsupported.
Children’s knowledge of their illness should be assessed
and an age-appropriate process of gradual knowledge-
building started. Increasingly, clinicians now address issues
of disclosure at an earlier age than previously [99], with
awareness that early, general discussions focusing on
healthy diet and lifestyle and knowledge about the blood
and immune system can provide a useful foundation for
later, specific discussions about HIV. It will generally be
appropriate for most children to know their HIV status (i.e.
for the disease to be named) before adolescence (i.e. from
age 9–10 years), although the timing of naming HIV will
vary according to the young person’s pre-existing knowl-
edge, maturity and developmental age, and the process can
be initiated earlier if deemed appropriate by the family and
the multidisciplinary team (reviewed in [100]). This process
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may be delayed in children with significant cognitive/
learning difficulties. Once disclosure is complete, adoles-
cents should understand the risks of onward sexual
transmission, and safe sex and contraception should be
regularly addressed. Giving young people an opportunity
to speak with clinic staff on their own is an important part
of this process. Appropriate services for adolescents with
perinatally acquired HIV infection and the management of
transition of their care to adult services are discussed in
Section 13.
8. Monitoring on ART
• The aim of ART is to achieve an undetectable VL (< 50
copies/ml plasma) and CD4 reconstitution.
• Laboratory monitoring for drug toxicity should be per-
formed initially within 2–4 weeks of starting a new drug,
then at least every 6–8 months if there are no ongoing
toxicity concerns.
• After starting ART, VL should be checked early (at
around 1 month) to confirm that VL is decreasing (this
can coincide with toxicity monitoring).
• VL and CD4 count can then be monitored 3−4-monthly
once the patient has been established on treatment.
• Once CD4 cells are reconstituted and VL has been < 50
copies/ml consistently for over 1 year, CD4 parameters
can be monitored less frequently (every 6–8 months, i.e.
at alternate clinic visits).
• More frequent clinical and laboratory monitoring is
required:
• in infancy;
• if adherence is poor;
• soon after starting or changing therapy (e.g. Liver
function tests should be performed within 2 weeks);
• in the context of ongoing drug toxicity;
• when giving medications with significant drug inter-
actions with ART, such as antituberculous therapy.
Clinical and laboratory monitoring requirements for chil-
dren on ART are similar to those of ART-naïve children (see
Section 3). In addition to the routine clinical, growth,
development, urinalysis, vaccination status/immunity and
laboratory monitoring, it is important to check specifically
for adherence to therapy, side effects and the need for dose
modification with changing age and weight. Other current
medications should be regularly reviewed, as there is
potential for ART to interact with medication obtained
from other sources (e.g. oral contraceptive, inhaled steroids
and antacids). Other medical teams who may prescribe such
medication (e.g. family doctors) should be informed of the
potential for drug interactions when children are started on
ART. Monitoring needs to be more frequent in infancy and
shortly after initiating or changing therapy, but once chil-
dren are established on treatment and stable, clinic visits
can be 3–4-monthly. In order to minimize disruption to
schooling, appointments can be made after school or to
coincide with school holidays.
Recent modifications to adult guidelines have recom-
mended less frequent laboratory monitoring in those on
long-term suppressive ART [2]. The results of the ARROW
trial in children have also shown clinical monitoring to be
a safe and effective alternative to laboratory monitoring, in
resource-poor settings [71]. This supports a recommenda-
tion that monitoring of CD4 count and laboratory tests
for drug toxicity can safely be performed less frequently
than every 3 months when a child is clinically well, has had
VL < 50 copies/ml for over 1 year and is not severely
immunosuppressed.
TDM of NNRTIs and PIs is available in several quality-
controlled laboratories in Europe. There are no studies to
inform recommendations for routine use of TDM in chil-
dren, but it may be particularly useful where there is: (1)
suspicion of drug toxicity, poor adherence or drug inter-
actions (e.g. TB treatment); (2) failure to suppress viraemia
despite good reported adherence; (3) renal or hepatic dys-
function; (4) use of unlicensed dosing regimens [101,102].
More evidence is required regarding the utility of TDM in
monitoring use of drugs with highly variable PK (e.g. EFV).
TDM may also be considered in infants and neonates, or
with new drugs where PK data are less well established.
TDM is generally not indicated for NRTIs as intracellular
levels of the active metabolite are difficult to measure/
interpret and large blood volumes are required.
One effect of starting ART may be immune reconstitu-
tion inflammatory syndrome (IRIS). This occurs within a
few weeks or months after starting therapy, is often asso-
ciated with an exaggerated immune response to an under-
lying opportunistic infection and is not specific to any
drug. The diagnosis is clinical and requires the exclusion of
active infection and drug toxicity. Symptoms can be severe
and may need treatment with anti-inflammatory drugs
(e.g. steroids) and additional therapy for underlying oppor-
tunistic infection. In the majority of cases ART should be
continued.
9. Drug toxicities and interactions
• Toxicities depend on the individual drugs and ART com-
bination and should be assessed at each clinic visit.
• Drug interactions should be considered when starting
new medications in a child on ART. Use http://www.hiv-
druginteractions.org/ to check drug interactions and
toxicities.
• See Table 5 for common ART-associated toxicities.
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Drug toxicity has been a major limitation of ART to date,
and one of the aims of modern ART regimens is to reduce
side effects. Side effects can be acute, appearing early
(usually within days to a few weeks after initiation), or late,
declaring themselves after prolonged use of particular
antiretrovirals.
Acute toxicities can be caused by any antiretroviral and
include nausea, diarrhoea, headache, rash [mild to severe
dermatological manifestations, such as Stevens−Johnson
syndrome (SJS)], liver dysfunction (from asymptomatic
elevation of liver enzymes to drug-induced hepatitis) and
allergic reactions (Table 5). If severe events occur, ART
should be discontinued with a subsequent replacement of
drugs suspected to have caused the reaction (see Section 11
on switching). Some side effects, such as vomiting and
diarrhoea, are transient and tend to resolve with time, but
close monitoring and supportive/symptomatic treatment
may be required.
Early adherence may be affected by common side effects
that cause significant disturbance to daily life – for
example diarrhoea caused by LPV/r, dysphoria caused by
EFV, and nausea or headache caused by ZDV. Patients and
their carers should be counselled appropriately prior to the
start of ART and necessary support and close liaison should
be assured during the first few weeks.
In the longer term, specific organ dysfunction,
haematological complications and metabolic disturbances
including mitochondrial toxicity, bone mineral loss,
lipodystrophy, elevated cholesterol and triglycerides, and
altered glucose homeostasis may occur. A recent cohort
study of European children reported that nearly half
had signs of fat redistribution and nearly a quarter had
an abnormal lipid profile [103]. Risk factors included
advanced HIV disease, and use of d4T, NNRTIs, PIs and
triple-class ART. The relationship between lipodystrophy
and ART is complex because of multiple exposures to
different antiretrovirals and physiological changes in body
composition during childhood and adolescence. Late side
effects should be monitored for and addressed appropri-
ately at every visit (see Section 8).
A number of studies have documented increased rates of
cardiovascular and cerebrovascular disease in HIV-infected
adults, which appear to be multifactorial and relate both to
HIV disease itself and ART, with the greater risk associated
with PIs and ABC [104,105]. Several mechanisms have been
postulated, including metabolic and lipid derangement
(especially related to PI), insulin resistance, direct vascular
injury and increased inflammation [106]. Some studies in
children have shown an increase in markers of cardiovas-
cular risk such as immune activation markers, carotid
Table 5 Common side effects of antiretroviral therapy in children*
Toxicities Antiretrovirals
Neuropsychiatric symptoms/insomnia/other CNS symptoms Efavirenz, raltegravir and atazanavir
Neuropathy Didanosine, stavudine and zidovudine
Myopathy Zidovudine
Headache All antiretrovirals
Nausea and vomiting All antiretrovirals, in particular zidovudine and protease inhibitors
Diarrhoea Protease inhibitors (in particular lopinavir) and didanosine
Pancreatitis Didanosine, stavudine and raltegravir
Hepatitis/liver toxicity/liver dysfunction All antiretrovirals (in particular nevirapine and didanosine).
Indinavir and atazanavir cause hyperbilirubinaemia
Renal dysfunction Tenofovir and atazanavir
Bone demineralization/osteopenia/osteoporosis Combination antiretroviral therapy, especially following initiation, regardless of regimen;
in particular, protease inhibitors, tenofovir and stavudine
Severe dermatological conditions (SJS/EM major/TEN) All antiretrovirals, in particular, nevirapine, efavirenz, etravirine, fosamprenavir, abacavir,
darunavir, zidovudine, didanosine, boosted lopinavir and atazanavir
Rash All antiretrovirals, in particular NNRTIs
Skin hyperpigmentation Emtricitabine (more prominent in non-Caucasians)
Systemic hypersensitivity reaction Abacavir, nevirapine and enfuvirtide
Lipodystrophy All protease inhibitors and efavirenz (lipohypertrophy).
Didanosine, stavudine and zidovudine (lipoatrophy)
Dyslipidaemia All protease inhibitors, NRTIs, especially stavudine, and NNRTIs (efavirenz > nevirapine)
Glucose intolerance NRTI thymidine analogues (stavudine, didanosine and zidovudine).
Some protease inhibitors (ritonavir-boosted lopinavir; less often atazanavir and fosamprenavir)
Lactic acidosis NRTIs, in particular, didanosine and stavudine (enhanced in combination); less commonly zidovudine
Granulocytopaenia, neutropaenia and/or anaemia Zidovudine and fosamprenavir
Respiratory symptoms Abacavir, lamivudine and zidovudine
CNS, central nervous system; SJS, Stevens−Johnson syndrome; EM, erythema multiforme; TEN, toxic epidermal necrolysis; NRTI, nucleoside reverse
transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor.
*The list is not exhaustive; for a complete list, refer to the summary of product characteristics (http://www.ema.europa.eu/ema/) and DHHS website
(http://aidsinfo.nih.gov/drugs).
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intima-media thickness (IMT) and carotid-radial pulse-
wave velocity [107–109]. Other adverse effects related to
specific organ dysfunction, such as CNS disorders, renal
abnormalities, hepatitis or bone loss, may also be attribut-
able to either ART or HIV itself. The SMART trial in adults
has been important in demonstrating that treatment with
ART results in fewer such problems than withholding drugs
[51].
9.1 Common toxicities with antiretrovirals
used in children
NNRTIs
The main toxicity of EFV is neuropsychological symptoms
(e.g. bad dreams, mood swings, drowsiness, dizziness,
impaired learning and depression) which anecdotally
may be worse in older children (possibly secondary to a
reporting bias). This should be borne in mind when con-
sidering which drug to use in children with established
psychological/neurological disturbance. Other complica-
tions associated with EFV are dyslipidaemia, abnormal fat
distribution [103] and gynaecomastia.
NVP may be associated with skin rash, hepatitis and SJS,
which typically occur within the first few months of expo-
sure. Rash and hepatic dysfunction are less common
when a 2-week half-dose lead-in dosage is used. NVP
should not be used in children with liver dysfunction or
co-administration of other hepatotoxic drugs. Prolonged-
release tablet formulations are available for children > 6
years old and produce a more even drug exposure, but are
not suitable for the 14-day lead-in phase when starting
NVP. Rash is much less common with EFV than with NVP;
however, there are insufficient data to recommend switch-
ing from NVP to EFV in cases of dermatological hypersen-
sitivity reactions, as repeat rash after substitution has been
reported to occur in more than 12% of adult patients [110].
PIs
PIs are associated with dyslipidaemia and lipodystrophy
[103,111–113]. However, once-daily PIs, such as ATV/r and
DRV/r, in adults tend to cause fewer lipid abnormalities
[114–116]. Measures to improve dyslipidemia can include
lifestyle modifications (diet and exercise) and change of
ART to ‘lipid friendly’ antiretrovirals (NVP, ATV/r, DRV/r
and RAL). In rare cases when no effect is seen from ART
substitution, lipid-lowering agents, such as statins, may be
used. However, in view of their frequent side effects and
drug interactions with antiretrovirals, this ideally should be
done in consultation with experts in ART and lipid agents.
The common side effect of ATV in children is
hyperbilirubinaemia, which was reported in 45% of treated
children in clinical studies [117]. It is not associated with
elevation of liver enzymes, and often improves with time.
In cases when hyperbilirubinaemia is significant and jaun-
dice is noticeable by the patient’s peers, consideration
should be given to substitution of the drug with an alter-
native agent.
NRTIs
A rare but clinically important early side effect is ABC
hypersensitivity associated with the presence of HLA
B*5701.This may be fatal if the drug is reintroduced after a
reaction. Possible cardiovascular toxicity of ABC in adults
remains controversial. A meta-analysis of RCTs did not
find an increased cardiovascular risk [118] and the biologi-
cal mechanism of possible cardiovascular toxicity of ABC
has not been established. To date, no link to cardiovascular
toxicity has been found in ABC-exposed children.
TDF is associated with bone and renal toxicity, preclud-
ing its use as a preferred NRTI in younger children. Studies
of TDF-associated bone toxicity in treatment-experienced
children yielded conflicting results [119]. A significant loss
of bone mineral density (BMD) was observed in young and
pre-pubertal children, and in those who received higher
exposures to TDF because of higher doses or concomitant
use of PIs [120,121]. Reassuringly, in most children
on TDF-containing ART, BMD z-scores after an initial
decrease tend to stabilize [121–123]. Although the clinical
significance of delayed bone mineralization has not been
established, the concern is that suboptimal bone accrual
in childhood and failure to achieve expected peak bone
mass could result in increased fractures in adulthood. Pae-
diatric data on TDF renal toxicity are also controversial,
showing conflicting results from no renal dysfunction to
increased rates of proteinuria and hypophosphataemia
[124]. Extrapolating from adult studies showing that renal
dysfunction is associated with increased TDF plasma levels
and PI use [125], dosing accuracy and meticulous attention
to monitoring for renal dysfunction in children, especially
in those who are on concomitant PIs, are of particular
importance.
The use of NRTIs, in particular d4T, ddI and to a lesser
extent ZDV, is associated with lipoatrophy, peripheral neu-
ropathy, lactic acidosis and other toxicities linked to
mitochondrial damage. Noncirrhotic portal hypertension
has been reported as a rare complication of exposure to ddI
in adults [126–128] and children [129,130], may be asso-
ciated with a genetic predisposition [126] and can become
evident after ddI has been discontinued. PENTA does not
support the use of d4T or ddI in first- or second-line ART.
However, in cases of multiple resistance, if no alternatives
are available, ddI may be used to construct a fully active
ART regimen. It should be noted that ddI should not be
used together with TDF in view of increased toxicity. ZDV,
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still frequently used in paediatrics, affects bone marrow,
causing macrocytic anaemia and neutropenia, and rarely
thrombocytopenia or bone marrow suppression with pan-
cytopenia [131]. 3TC and FTC are generally well tolerated;
however, they can cause allergic reactions and constitu-
tional symptoms.
INSTIs
RAL and DTG have a very good safety profile in adults and
are well tolerated, although data on long-term exposure are
more limited. The most common adverse effects reported
in adult patients are constitutional symptoms (fatigue,
nausea, dizziness, insomnia and headache), rash, diarrhoea,
abnormal liver function tests and raised creatinine kinase.
Hypersensitivity reactions have been reported and were
characterized by rash and, in some cases, hepatic failure.
Fusion and entry inhibitors
These two classes of drug are not recommended for first-
line use and are discussed in more detail in Section 11. The
CCR5 receptor antagonist maraviroc (MVC) is not licensed
for patients under the age of 18 years. Paediatric studies on
safety and efficacy in children are ongoing [132]. In adults,
MVC is generally well tolerated but has been associated
with hepatic toxicity, severe skin and hypersensitivity reac-
tions and postural hypotension. The HIV fusion inhibitor
enfuvirtide (T20) is almost universally associated with
injection site reactions but is otherwise well tolerated apart
from mild constitutional symptoms.
For detailed side effects of individual medicines, useful
resources include the Electronic Medicines Compendium
(http://www.medicines.org.uk/emc/), DHHS website
(http://aidsinfo.nih.gov/drugs) and EMA website (http://
www.ema.europa.eu/ema/). For all drugs, the effects of
prolonged use for decades remain to be seen, and this will
be of greater significance as more children start ART at an
earlier age.
9.2 Drug interactions
It is widely known that drug−drug interactions are impor-
tant in HIV treatment in adults; this is true for children as
well, although the frequency and type of comorbidities and
related co-medication may be different. ART can both be
affected by drug interactions (i.e. the plasma concentra-
tions of the ART may be changed) and/or be the cause of
a drug interaction (i.e. the ART influences the plasma
concentration of another drug). Increased toxicity or
therapy failure may occur.
Many of the drug interactions occur as the result of
drug-induced modification of cytochrome P450 (CYP450)
enzyme activity, although other systems, such as mem-
brane transporters [e.g. P-glycoprotein (P-gp) or UDP-
glucuronyltransferase (UGT)], may be relevant too.
ART as the cause of a drug interaction
There are a few general rules to remember: PIs are generally
inhibitors of CYP450 3A (CYP3A and other isoenzymes) or
P-gp and can lead to increased levels of co-administered
medication. This is, for instance, the case with inhaled
corticosteroids, oral contraceptives, benzodiazepines,
statins, antidepressants, etc. Both ritonavir and cobicistat
are specifically used together with PIs or EVG for their
ability to strongly inhibit liver enzymes and increase blood
concentration of their co-administered antiretroviral. The
NNRTIs NVP, EFV and etravirine (ETR) are enzyme inducers.
They generally reduce the plasma levels of any agents
metabolized via the CYP450 pathways with potentially
suboptimal therapeutic response.
Drug interactions affecting ART
The greatest risk for ART in terms of drug interaction is
when antiretroviral drugs are combined with other enzyme
inducers such as rifampicin, carbamazepine and phenytoin.
Lower plasma concentrations of the ART can lead to the
development of resistance and treatment failure.
Management of drug interactions
In the large majority of cases, drug interactions can be
managed by selecting the appropriate co-medication or
change in ART. TDM of the ART or co-medication might
be helpful. We recommend referring to http://www.hiv
-druginteractions.org to assess potential drug interactions
with ART, and that a pharmacist is included in the multi-
disciplinary team.
10. Coinfections
10.1 HBV and HCV
• Untreated HIV infection increases the progression of
liver disease in HBV or HCV coinfection.
• HBV and HCV coinfections both increase the risk of
hepatotoxicity with ART (especially NVP).
• Drugs used to treat HBV may select for resistant HIV and
vice versa.
• Liver disease in children with HBV or HCV coinfection
should be managed jointly with paediatric experts in
viral hepatitis.
• HCV coinfection is an indication for starting ART.
• For HBV coinfection, if treatment of HIV is not indicated
and there is no evidence of liver disease, HIV treatment
should be considered but may be deferred.
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10.1.1 Screening for viral hepatitis
Baseline screening
All children with HIV infection should be screened for viral
hepatitis when they first present. Screening should include
the following:
(a) Testing for coinfection, past infection or immunity to
HBV. This should include the following markers: HBV
surface antigen (HBsAg), HBV core antibody (HBcAb)
and HBV surface antibody (HBsAb). Children diagnosed
with HBV coinfection should be screened for hepatitis
delta virus (HDV) with HDV immunoglobulin M (IgM)
and IgG and HDV RNA PCR.
(b) Testing for coinfection with HCV. This should include
HCV antibody and HCV RNA PCR when available, as
rates of 3–13% of HCV-seronegative infection have
been reported in HIV-infected adult and paediatric
cohorts [133–135]. HCV antigen might be used by some
laboratories in screening algorithms. As data on the use
of this marker in paediatric infection are lacking, HCV
RNA is currently preferred.
(c) Testing for immunity to hepatitis A virus (HAV) infec-
tion (HAV IgG).
Vaccination for hepatitis A and B of seronegative children
should be recommended if a child is found to be seronega-
tive and levels of HBV antibody should be assessed regu-
larly and booster vaccinations or repeated courses given as
required [21]. Annual screening for HCV is recommended
in adolescence and adults in case risk factors exist such as
use of recreational drugs and/or sexual exposure.
Screening of infants exposed to HBV or HCV
When the mother is coinfected with HBV, screening of the
exposed infant should include HBsAg, HBsAb and HBcAb at
around 14–15 months of age following the last (fourth)
vaccination at 1 year of age. Infants born towomen coinfected
with HCV should be screened for evidence of HCV. In most
centres this screening includes a combination of PCR for
detection of HCV RNA in infancy as well as HCV antibody at
12–18 months when maternal antibody is expected to wane.
HCV RNA-positive results in infancy do not equate to long-
term infection, and follow-up is required as a small proportion
of HCV-monoinfected children will undergo spontaneous
clearance of infection within the first 3–5 years of life
[136,137]. Published data are sparse on the rates of sponta-
neous HCV clearance in HIV coinfected children.
Investigation of deranged liver function tests
In the case of unexplained deranged liver function tests
and/or liver disease, viral hepatitis should be considered,
including HAV, HBV, HCV, CMV and Epstein−Barr virus
(EBV) infection. Screening should ideally include: HAV IgM
and IgG, HBsAg, HBcAb, HBVDNA, HCV RNA, HEV IgM and
IgG, HEV RNA, CMV IgM and IgG, and EBV serology.
Alternative diagnoses for persistent transaminitis, such as
nonalcoholic fatty liver disease, autoimmune hepatitis, Wil-
son’s disease, alpha-1 antitrypsin deficiency, coeliac disease
and muscular dystrophy, should be considered.
HBV or HCV coinfection is a risk factor for hepatocel-
lular carcinoma (HCC). HCC is rare in childhood and more
data are required to evaluate the best approach to moni-
toring for this complication. Adult guidelines recommend
monitoring for HCC with 6–12-monthly serum alpha-
fetoprotein and liver ultrasound in all HBV-coinfected
patients and in HCV-coinfected patients with cirrhosis
[138,139]. In the absence of better monitoring methods,
this guidance is endorsed for children and adolescents.
10.1.2 HBV coinfection
In adults, there is a well-documented interaction between
HIV and HBV infection, with increased rates of liver
disease. Long-term follow-up data for coinfected children
are sparse but, in view of the concern about an increased
risk of liver disease progression in adult life, ART should be
considered in coinfected children regardless of clinical
stage or CD4 cell count. 3TC, FTC and TDF have activity
against HIV and HBV. They therefore should only be
administered as part of fully active ART in order not to
select for HIV resistance. In addition, treatment with 3TC or
FTC without TDF may quickly select HBV resistance to
these drugs and also reduce sensitivity to entecavir, thus
compromising future HBV treatment options [140]. Com-
binations of TDF with FTC or 3TC have been shown to
increase HBV viral clearance in HBV-coinfected adults
[139]. We recommend that two active drugs against HBV
(TDF/3TC or TDF/FTC) should be given, unless this is not
possible because of prior treatment that has selected for
resistant HBV strains. In children > 2 years of age, we
recommend starting TDF/3TC or TDF/FTC. In children with
HBV infection under 2 years of age, for whom TDF is not
yet licensed, if treatment for HBV infection is not required
(see treatment algorithm for paediatric patients with
chronic hepatitis B infection [141]), there are two options:
either starting (1) 3TC/FTC-sparing ART (unless HLA
B*5701 positive this would be ABC/ZDV) in order to avoid
3TC/FTC monotherapy and selection for HBV resistance or
(2) TDF-containing ART (off-licence TDF in this age group)
with careful monitoring of TDF bone and renal toxicity.
Children with evidence of past HBV infection (HBsAg
negative and HBcAb positive) are at risk of reactivation and
ideally ART should include an agent active against HBV. The
clinical implications of the rare phenomenon of occult
hepatitis B (HBsAg negative, with low replication in the liver
and plasma; usually HBV DNA well below 1000 IU/ml) are
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not clear. These patients should also be treated with ART that
contains an agent active against HBV.
Some anti-HBV drugs (such as entecavir and
telbivudine) have partial activity against HIV, which is
insufficient to fully suppress HIV but is sufficient to select
for resistance mutations. These drugs should not be used to
treat HBV infection in HIV-coinfected patients without
an accompanying fully suppressive ART regimen. In an
HBV-coinfected child on ART who develops TDF toxicity or
intolerance, the options are very limited. Extrapolating
from adult guidelines [139], entecavir as an add-on drug to
fully suppressive ART can be used in older children with
TDF intolerance. Children with HBV coinfection who dis-
continue anti-HBV antivirals are at risk of HBV reactiva-
tion and need to be monitored closely with clinical reviews
and liver function tests. Seek expert advice for the appro-
priate management of HBV-coinfected children.
10.1.3 HCV coinfection
HCV coinfection also increases the risk of liver disease, but
long-term follow-up data for coinfected children are
sparse. No anti-HIV ART drugs are effective against HCV.
In older children and adults, HCV coinfection is associated
with more rapid HCV progression [142,143] and may also
have an adverse effect on HIV progression [142], and
therefore early HIV treatment is recommended. Currently
in children only combination treatment with pegylated
interferon (PEG-IFN) and ribavirin can be used to treat
HCV infection. New direct-acting antiviral agents (DAAs)
against HCV have been approved for treatment of liver
disease in adults, and phase III trials of many other
compounds are under way. It is anticipated that PEG-IFN-
free regimens will be available for adults and children in
the near future, particularly for genotype 1 and 4 infection.
In children with HCV coinfection, debate is ongoing as
to whether clinicians should treat HCV infection immedi-
ately or wait for better treatment options. Some experts
prefer starting treatment earlier as there is better treatment
response and tolerability of PEG-IFN and ribavirin in chil-
dren compared with adults [144,145]. This may be espe-
cially relevant for patients with HCV genotypes 2 and 3, for
whom sustained virological response with PEG-IFN and
ribavirin over 24 weeks is much better than for genotype 1
(sustained virological response in HCV-monoinfected chil-
dren 89–93% [146,147]. However, PEG-IFN has an adverse
effect on growth in children, and the risk−benefit ratio
should be carefully considered during growth spurts [148].
Some specific interactions to consider include:
• ribavirin enhances intracellular phosphorylation of ddI;
fatal lactic acidosis has been described, and therefore ddI
should be avoided;
• ribavirin and ZDV both may cause anaemia;
• ABC may reduce ribavirin efficacy;
• d4T may cause mitochondrial (liver) toxicity;
• ATV may increase hyperbilirubinaemia, but there is no
clear evidence that this is worse in HCV-coinfected
children.
Seek expert advice for the appropriate management of
HCV-coinfected patients.
10.2 TB coinfection
• All HIV-infected children exposed to an individual with
infectious TB and all children with evidence of latent TB
infection should have preventive TB treatment (once
active TB disease has been excluded).
• In children with active TB disease, TB treatment should
be started at TB diagnosis. ART should be started as soon
as practicable, and within 2 and 8 weeks of TB treatment
in children with severe and moderate immunosuppres-
sion, respectively. ART may be deferred at higher CD4
counts until TB treatment is completed.
• There is significant interaction between ART and TB
therapy. TDM, where available, should be used in the
context of potential significant interactions.
• Children with TB coinfection should be managed in
consultation with an expert in the treatment of paedi-
atric TB. A specialist in DRTB should be involved in the
management of DRTB contacts and cases.
• See Table 6 for ART choices in children with TB.
Table 6 Antiretroviral therapy (ART) regimens for children treated for
tuberculosis (TB) coinfection with rifampicin-containing regimens
< 3 years > 3 years
Initiating ART Preferred LPV/R*,† + 2 NRTIs
NVP†,‡,§ + 2 NRTIs
EFV + 2 NRTIs
Alternative N/A LPV/R*,† + 2 NRTIs
DRV/r† + 2 NRTIs
ATV/r† + 2 NRTIs
Already on ART Preferred LPV/R*,† + 2 NRTIs
NVP†,§ + 2 NRTIs
EFV + 2 NRTIs
Alternative 3 NRTIs¶ LPV/R*,† + 2 NRTIs
ATV/r† + 2 NRTIs
DRV/r† + 2 NRTIs
3 NRTIs¶
ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir;
EFV, efavirenz; LPV, lopinavir; NRTI, nucleoside reverse transcriptase inhibi-
tor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nevirapine;
N/A, not available.
*Superboost lopinavir with increased ritonavir dose (R) to achieve
lopinavir/ritonavir ratio of 1:1. Return to regular dosing once rifampicin
has been discontinued. †Therapeutic drug monitoring is recommended
(where available) to adjust doses. ‡Start nevirapine (NVP) without lead-in
dose and at the maximum recommended dose for age. §Two weeks after
starting NVP, consider increasing the NVP maintenance dose by a further
20–30%. Watch for liver toxicity. Return to regular dose once rifampicin
has been discontinued. ¶In virally suppressed children.
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HIV-infected children are at increased risk of acquiring
TB infection and progression from latent to active TB
compared with HIV-negative children [149,150]. In the
combination ART era, in both high and low TB prevalence
countries, TB incidence is decreasing, but remains substan-
tially higher in HIV-positive children [151–154].
10.2.1 Management of children with TB exposure and
latent TB infection
All HIV-infected children should be screened for TB infec-
tion at HIV diagnosis with clinical examination, TST or
IGRA and chest X-ray (see Section 3). Preventive TB treat-
ment has been shown to effectively reduce the incidence of
TB disease in HIV-positive children exposed to an infectious
TB source case [155]. We recommend that all HIV-infected
children exposed to an individual with infectious TB and all
those with evidence of latent TB infection (positive TST or
IGRA) and no clinical or radiological signs suggestive of TB
disease should have preventive TB treatment.
A Cochrane review of preventive regimens in HIV-
infected individuals aged over 13 years found no difference
in incidence of TB disease between a 6-month regimen
with isoniazid monotherapy and 3 months of treatment
with co-administered isoniazid and rifampicin. However,
the combination regimen was associated with more
discontinuations because of adverse effects [156]. A few
paediatric studies have shown that a 3-month regimen of
isoniazid and rifampicin treatment is safe and effective
[157,158]. Therefore, we recommend that children with HIV
infection who have been exposed to TB or have latent TB
infection and who are not receiving ART can be treated
with either 3 months of isoniazid and rifampicin or 6−9
months of isoniazid (according to local policy in HIV-
uninfected children); for those on ART, in view of drug
interactions, the preferred preventive treatment is 6–9
months of isoniazid. For children exposed to drug-resistant
TB, preventive therapy should be decided on an individual
basis in consultation with a TB expert. Preventive treat-
ment should only be administered once active TB has been
excluded. Children with nonspecific chest X-ray changes,
and no improvement after the course of treatment for their
suspected underlying respiratory illness (lymphocytic
interstitial pneumonia, chest infection), should be treated
for possible TB disease (see below).
10.2.2 TB disease in HIV-infected children
There are particular difficulties relating to TB diagnosis,
drug interactions and immune reconstitution disease in
HIV-infected children coinfected with TB. Negative results
of a TST or IGRA cannot be used to rule out TB disease
[159,160]. Every effort should be made to make a confirma-
tory microbiological diagnosis but this is often not possible.
New technologies such as Genexpert (Cepheid, California,
USA) can expedite diagnosis while providing early informa-
tion on rifampicin sensitivity [161]. Anti-TB treatment
should always be started at TB diagnosis. All HIV-infected
children diagnosed with TB should also be started on ART;
however, the optimal timing of ART initiation depends on
the degree of immunocompromise. Adult RCTs showed
significant reduction in mortality and progression to AIDS
with earlier ART in patients with CD4 counts < 50 cells/μl
(Starting ART at 3 Points in TB (SAPIT) [162], Cambodian
Early versus Late Introduction of Antiretrovirals (CAMELIA)
[163] and Immediate Versus Deferred Start of Anti-HIV
Therapy in HIV-Infected Adults Being Treated for Tubercu-
losis (STRIDE) [164]). A retrospective study in South African
children, most of whomwere severely immunocompromised
with median CD4 percentage < 12%, also showed that delay
of ART for longer than 2 months was associated with
increased mortality and worse virological response [165].
Therefore, children with severe immunosuppression should
start ART within 2 weeks of beginning TB treatment, and
those with moderate immunosuppression within 8 weeks.
Data in adults suggest that delayed ART in patients with no
or mild immunocompromise is not associated with worse
outcomes. The potential benefits of delayed ART in this
group are decreased pill burden and drug interactions,
which may lead to better drug tolerance and adherence, as
well as reduced occurrence of IRIS. There are insufficient
data in children with no or mild immunocompromise but,
based on the results of adult studies, delaying ART until TB
treatment is well tolerated (or even completed) can be
considered. The optimal time for ART initiation in the
context of TB meningitis remains to be determined.
In the absence of TB drug resistance, standard TB
treatment with isoniazid, rifampicin, pyrazinamide and
ethambutol is recommended. Rifampicin, a potent CYP3A4
inducer, has significant interactions with other medicines
metabolized through CYP450 enzymes, reducing their
blood levels. Considerable interaction occurs when
rifampicin is co-administered with NVP or PIs, whereas
interaction with EFV is less significant and achieving
therapeutic levels is possible without dose alteration. If
available, rifabutin may be used instead of rifampicin to
reduce drug interactions. In settings where TDM is avail-
able, dose adjusting of antiretrovirals and rifampicin/
rifabutin is recommended. The choice of ART in children
co-treated for TB depends on the child’s age, whether the
child is receiving ART or starting ART, history of previous
ART exposure and availability of TDM (Table 6).
In ART-naïve children less than 3 years of age on TB
therapy, it is recommended to start with LPV/r-based ART
with added ritonavir to achieve an LPV/ritonavir ratio of
1:1 (superboosting) [166,167]. Alternatively, ART-naïve
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children under 3 years of age can be started on NVP-based
ART but without lead-in dose and at the maximum rec-
ommended dose (200 mg/m2 twice daily). A PK study in
children aged < 3 years co-treated for TB with rifampicin
showed suboptimal exposure to NVP on a 300–400 mg/m2
daily dose [168]. In order to obtain better exposure in
younger children, the maintenance dose can be further
increased by 20–30% 2 weeks after starting treatment (H.
Lyall and S. Welch, unpublished data). The doses of both
rifampicin and NVP can be further adjusted with the results
of TDM. NVP should be decreased back to a regular 300–
400 mg/m2 daily dose 1–2 weeks after stopping rifampicin.
In settings where TDM is not available, superboosted LPV/
r-based ART is a preferable option in children under 3
years of age initiating ART. Recently, EFV sprinkles were
approved by the FDA for children aged 3 months to 3 years
[74,75]. Further PK, efficacy and safety studies in chil-
dren < 3 years old receiving anti-TB treatment are under
way. Until the results are available, the use of EFV sprinkles
in younger children receiving treatment for TB cannot be
widely recommended.
In children aged below 3 years who are already on ART,
the options for adjusting doses of antiretrovirals discussed
above are applicable. A recent RCT [71] showed that a
triple-NRTI maintenance regimen (ABC + 3TC + ZDV) is
immunologically and clinically similar to NNRTI-based ART
and can be valuable in children with controlled HIV infec-
tion who develop TB, and is an alternative regimen.
For children aged over 3 years initiating ART, the
preferred regimen is EFV-based ART. Children aged > 3
years who have been receiving NVP should be switched to
EFV. If EFV cannot be used (because of NNRTI resistance,
neurocognitive problems or suboptimal predicted adher-
ence), an alternative option is superboosted LPV/r as above
or other PI-based ART. For PI-based ART, TDM should be
used where available.
Children aged over 3 years who have been receiving
PI-based ART can continue on their regimen with adjust-
ment of PI doses as above, or they can be switched to EFV.
A triple-NRTI regimen is another alternative option.
RAL has been shown to be an effective option in the
treatment of HIV/TB-coinfected adults [169]. There are no
data available for coinfected children. RAL cannot therefore
be routinely recommended as a treatment option at present;
however, its use can be considered with specialist advice and
TDM. Data on the use of DTG in this context are awaited. The
duration of TB treatment depends on the response to TB,
which in turn depends on the degree of immunocompromise
and the extent of TB disease. There are no comparative
studies suggesting that the duration of TB treatment should
be prolonged in HIV-infected children. In uncomplicated TB,
the duration of treatment should be the same as in non-HIV-
infected children; however, if at the end of the treatment
there is an incomplete response, then TB treatment may be
extended [170]. Adherence, drug levels, drug resistance and
IRIS should be adequately addressed.
Drug-resistant TB should be managed in conjunction
with an expert. It should be treated with a TB regimen
chosen according to bacterial drug resistance and national
TB guidelines. Care needs to be taken to anticipate poten-
tial drug interactions and cumulative toxicities between
ART and the TB regimen; the choice of ART may be simpler
in TB regimens that do not contain rifampicin.
TB-associated immune reconstitution inflammatory syn-
drome (TB-IRIS) is not uncommon in children starting ART
[171–175]. TB-IRIS usually develops within 3 months of
starting ART, with higher risk in those patients with
advanced HIV disease, low pre-ART CD4 count and shorter
interval to starting ART after initiation of TB treatment
[175–177]. ART should be continued, but steroids may be
necessary to manage IRIS. Further details on management
of TB in HIV-infected children can be found in the WHO
and The International Union Against Tuberculosis and
Lung Disease (IUATLD) guidelines [6,170,178,179].
10.2.3 Opportunistic infections
The management of children presenting with opportunistic
infections can be complex, especially when a child presents
very unwell. These patients should ideally be managed on
a case-by-case basis. Generally it is recommended that ART
should be initiated as early as possible, apart from in the
context of cryptococcal meningitis, where a single RCT in
adults has shown that delaying ART may be associated
with reduced mortality [180].
11. When to switch, resistance testing and
second and subsequent ART regimens
ART regimens may be changed because of treatment
failure or toxicity, or during successful treatment for
simplification.
11.1 Virological failure – second and subsequent
regimens
• Switching to second-line therapy following virological
failure should occur early (VL > 1000 copies/ml) for
those failing on combinations including drugs with a
low genetic barrier to resistance (NNRTIs or RAL).
• Where there are blips in VL (detectable VL < 400 copies/
ml), blood tests should be repeated within 4 weeks to
confirm re-suppression.
• Reinforcement of adherence support, as the main reason
for treatment failure, should be prioritized. Switching
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treatment when there are ongoing problems with adher-
ence may lead to loss of efficacy of further classes of
ART.
• Table 7 summarizes potential strategies for choosing
second-line therapy. If the suggested options are not
applicable, seek expert advice.
Virological failure is almost always attributable to poor
adherence. In adult practice, ART is switched early if there
is detectable viraemia, because of the risk of accumulation
of further resistance mutations, which may make subse-
quent regimens less effective. PENPACT-1 randomized
ART-naïve children to two NRTIs with either an NNRTI or
a boosted PI. Those experiencing virological failure were
randomized to switch to second-line therapy at VL > 1000
copies/ml or > 30 000 copies/ml. Delayed switching
(VL > 30 000 copies/ml) on NNRTI-based ART was not
associated with poorer clinical outcome but was associated
with increased rates of NRTI resistance. Rates of NNRTI
resistance were similar irrespective of VL at the time of
switching, with NNRTI resistance being acquired early in
virological failure. Children failing therapy on boosted PIs
showed very low rates of PI and NRTI resistance irrespec-
tive of the timing of the switch to second-line therapy.
PENPACT-1 is the only paediatric RCT addressing the
timing of the switch to second-line therapy [70]. Accumu-
lation of NRTI resistance with delayed switching following
VL failure on NNRTI-based ART has also been reported in
paediatric cohort studies; however, the impact of this
resistance on clinical outcome has not been addressed
[181,182].
Considering the length of time they are likely to require
treatment, it is important that children have not used up all
ART options before adulthood. Sequencing of newer
classes of antiretroviral drugs should take into account
the CCR5 receptor antagonists (e.g. MVC), which are only
active against viral populations that use the CCR5
co-receptor for cell entry. The proportion of perinatally
infected adolescents with R5 variants, for whom MVC is a
potential option, is highly variable within cross-sectional
studies [183,184]. Co-receptor tropism should be performed
within 3 months of the proposed treatment switch that
includes MVC for those with detectable viraemia. Paediat-
ric studies of MVC are ongoing in treatment-experienced
children aged 2–18 years (http://clinicaltrials.gov/show/
NCT00791700).
Of note, as in adults, single VL blips (single VL
values > 50 but < 400 copies/ml that subsequently return
to < 50 copies/ml) do not predict subsequent virological
failure, but these should always be followed up as soon as
Table 7 Switching to second-line antiretroviral therapy (ART)
Age
Failed on first-line NNRTI backbone Failed on first-line boosted PI backbone
Resistance mutations No resistance mutations Resistance mutations No resistance mutations
All Evaluate/support adherence +++
Switch depending on resistance
Evaluate/support adherence +++
Switch to a more robust/forgiving
PI-based regimen (see below)
or
Restart same first-line regimen
Evaluate/support adherence +++
Switch depending on resistance
Evaluate/support adherence +++
Switch to a simplified regimen
(see below)
or
Restart same first-line regimen
< 6 years LPV/r + 2 active NRTIs (e.g.
TDF† + ZDV if first-line ART
was ABC + 3TC)
LPV/r + same first-line NRTIs DRV/r* + 2 active NRTIs (e.g. TDF† + ZDV
if first-line ART was ABC + 3TC)
or
DRV/r* + INSTI + 1 active NRTI
Simplification options, depending on
child’s weight (aim for once daily):
Boosted PI
Simpler formulations
Fixed dose combinations if
available for the child’s age
6–12 years ATV/r or DRV/r + 2 active NRTIs ATV/r or DRV/r + same first
line NRTIs> 12 years New regimen with at least 3 new active
drugs; e.g. boosted PI, NRTI, INSTI,
CCR5 inhibitor – seek expert advice
General principles:
1 Present your case to others with expertise in the field (e.g. ‘virtual clinic’). If switching to third-line or salvage therapy, always seek expert advice.
2 Resistance testing should be undertaken while the patient is still on or recently off a failing regimen. Results will direct second- line choices. If testing
is performed too late (more than 4 weeks) after cessation of a failing regimen, the results will probably show wild-type virus. If this is the case or if testing
is not available, resistance should be assumed.
3 Reinforce adherence support. This is the main reason for treatment failure.
4 Simplify regimens where possible (once-daily and fixed dose combinations). Switching to NNRTI-based regimens or PI monotherapy is not advised if there
are serious adherence issues.
5 If resistance results suggest that these second- line options in the table would not be effective, seek expert advice.
Seek expert advice if the patient is aged < 3 years and failing LPV/r with mutations and for any child < 2 years old failing first-line therapy with NRTI
mutations.
3TC, lamivudine; ABC, abacavir; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; INSTI, integrase inhibitor; LPV/r, ritonavir-boosted
lopinavir; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; NVP, nevirapine; TDF,
tenofovir; ZDV, zidovudine.
*DRV/r is not licensed for < 3 years of age.
†TDF is not licensed for < 2 years of age.
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possible, to make sure that they are not the beginning of
significant viral rebound [185].
In children, switching therapy after virological failure
should only be considered when adherence has been
reviewed. Failure of an NNRTI-based regimen is often a
result of viral drug resistance following poor adherence,
and switching to a boosted PI is appropriate. In resource-
rich settings, those failing NNRTI-based regimens should
not continue on NNRTI-based ART, to avoid the accumu-
lation of further NRTI and NNRTI mutations which will
impact on future ART options. Two strategies are available;
either a direct switch to PI-based therapy or a short period
off ART, if clinical status and CD4 count permit, while
adherence is further addressed, followed by PI-based ART.
Failure of a boosted PI-based regimen is more likely to
be caused by poor adherence than resistance. Children
failing PI-based regimens, without documented resistance
mutations, may continue their current regimen while
adherence is addressed. Simplified regimens using FDCs
and once-daily PIs should be considered. A switch to
NNRTI-based second-line therapy is likely to result in rapid
development of resistance to the new drugs and is not
recommended if adherence has not been addressed. If
resistance is detected then switching to an alternative PI
without overlapping resistance is the preferred option, with
the addition of an agent from a newer class (INSTI or CCR5
receptor antagonist) dependent on the resistance profile but
aiming for three active agents.
3TC and ABC may be switched to ZDV and TDF, the
latter now licensed for patients from 2 years of age. For
infants with first-line failure, ddI may be substituted
for TDF; however, recent case reports of noncirrhotic
portal hypertension in HIV-infected adolescents following
prolonged exposure to ddI are of concern [126–130].
Therefore, ddI exposure should be kept to a minimum
with substitution of an alternative agent at the earliest
opportunity.
Third and subsequent regimens are more complicated
and need to take into account all previous drug histories
and cumulative resistance mutations as well as the current
regimen. This will always require expert virologist input.
While virological failure with triple class exposure was
reported in 12% of children in Europe [186], rates of triple
class resistance are variable, ranging from 12 to 32% and
increasing with age [187,188]. Construction of effective
third-line and subsequent regimens, ideally with at least
two and preferably three fully active agents, requires
expert advice. Paediatric experience of combinations that
include INSTIs [189], T20 [190], ETR [191,192], MVC [132]
and DRV/r is accumulating.
For patients where a suppressive regimen cannot be
constructed with currently available ART, newer agents
should be obtained (and may be used off-label with expert
advice) through named patient and expanded access pro-
grammes and clinical trials. Single agents should not be
added to nonsuppressive regimens because of the risk
of accumulating further mutations impacting on future
treatment options. In this situation, nonsuppressive ART,
including 3TC or FTC, may be continued to prevent further
immunological decline.
As discussed above (Section 6), RAL and DTG have
recently been licensed for paediatric use. ETR, a second-
generation, twice-daily NNRTI, is licensed for treatment-
experienced children aged > 6 years. It is not fully cross-
resistant with NVP and EFV, but once more than two NNRTI
mutations are present its efficacy significantly decreases
[193]. RPV, a once-daily NNRTI, is licensed for patients > 18
years old. It is available as once-daily FDCwith TDF and FTC
(Eviplera). Although it has fewer CNS side effects than EFV,
a smaller pill size, and the possibility of co-administration
with oral contraceptives, the significant disadvantages of
increased virological failure rates in patients with VL
> 100 000 copies/ml and CD4 count < 200 cells/μL, higher
overall rates of resistance mutations compared with EFV-
containing regimens (phase 3 TMC278-C209 and TMC278-
C215 trials; FDA pooled analysis [194]), and administration
with a meal requirement preclude its use as a first-line drug
in most situations, but it can be considered in specific
circumstances (e.g. patient preference or substitution for
EFV intolerance). In young people with fully suppressed HIV
and a regular meal pattern (absorption requires ingestion
with a meal) [195], Eviplera may be considered for simpli-
fication, for example where there is intolerance to EFV-
based therapy. Ongoing studies in children will provide
important information on the place of ETR and RPV in
paediatric treatment strategies [IMPAACT P1090 (http://
clinicaltrials.gov/show/NCT01504841); IMPAACT P1111
(http://clinicaltrials.gov/show/NCT01975012)].
Table 7 summarizes potential strategies for choosing
second-line therapy.
11.2 Resistance testing
• Resistance testing should be performed prior to switch-
ing regimens when there is virological failure. Resistance
testing should be undertaken while the patient is still on
the failing regimen. If this is not possible, ideally test
for resistance within 4 weeks of stopping the failing
regimen.
• Resistance testing may include reverse transcriptase/
protease/integrase/V3 loop/envelope sequencing.
• The interpretation of resistance results can be guided
by the Stanford HIV Drug Resistance Database (http://
hivdb.stanford.edu/).
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• Substituting single drugs in a failing regimen without
prior resistance testing is not recommended.
Adding or substituting single drugs in a failing ART
regimen risks giving the new drug as effective
monotherapy, which may result in rapid development of
further resistance. It is therefore recommended that all
changes in therapy with detectable viraemia be preceded
by a resistance test. Ideally, resistance testing should be
performed on a sample taken while the patient was still on
the old regimen, or within a few weeks of stopping, when
mutant quasispecies of HIV are most likely to be detected.
Standard resistance testing includes sequencing of reverse
transcriptase and protease; however, those failing on
INSTIs and T20 require sequencing of integrase and
envelope, respectively. Children failing on CCR5 receptor
inhibitors require tropism assay/V3 loop sequencing to
assess whether dominant viral variant remains R5-tropic.
Expert opinion should be sought in interpreting resistance
genotypes. Guidance relating to specific mutations is
beyond the scope of these guidelines. The Stanford data-
base (http://hivdb.stanford.edu/) is a useful, regularly
updated resource. Resistance testing results should be dis-
cussed with an expert centre. If no local expertise is avail-
able then we recommend seeking advice from the PENTA
network.
11.3 Simplification
Where possible, regimens should be simplified (once-daily,
fixed dose combinations), but switching to NNRTI-based
regimens or PI monotherapy is not advised if there are
adherence issues.
Treatment simplification may involve reducing the
number of drugs or tablets as a child becomes older, chang-
ing from twice- to once-daily therapy, or changing from a
boosted PI-based regimen to an NNRTI-based regimen once
viral suppression is achieved and adherence is assured.
Simplification should not be carried out with detectable
viraemia because of the risk of selecting for resistance
mutations. Simplification is much easier as children reach
35−40 kg as adult co-formulations are available and once-
daily options include the following.
Three-drug FDCs:
EFV, TDF and FTC (Atripla);
RPV, TDF and FTC (Eviplera);
EVG, cobicistat, TDF and FTC (Stribild).
Dual NRTI combinations:
TDF and FTC (Truvada);
ABC and 3TC (Kivexa).
Children virologically suppressed on twice-daily boosted
LPV-based ART may benefit from simplification to once-
daily boosted PIs (ATV/r or DRV/r) when they are able to
swallow larger tablets, typically reducing daily pill burden
from five to three pills for those over 40 kg. Switching to
once-daily boosted PIs has been associated with improved
lipid profiles in adult studies and now this has been dem-
onstrated in a paediatric population [196].
Children suppressed on ARTmay also switch to reduce the
likelihood of ART toxicity. The Nevirapine Resistance Study
(NEVEREST), a randomized trial of switching NVP-exposed
infants from suppressive LPV/r- to NVP-based ART (after at
least 3 months of VL < 400 copies/ml), showed that this
strategy can be successful in infants without evidence of
transmitted NVP resistance on conventional testing
[64,197]. Children switched to NVP had less long-term
dyslipidaemia and subcutaneous fat loss [112]. Furthermore,
the recently reported results of the NEVEREST-3 study [198]
indicate that switching children fully suppressed on LPV/r to
EFV-based ART is a safe and effective strategy in the context
of prophylactic NVP exposure.
High rates of virological failure (without development of
resistance limiting future treatment options) were reported in
the Protease Inhibitor Versus Ongoing Triple-therapy (PIVOT)
trial of PI monotherapy in adults [199]. Reducing the number
of drugs below a standard three-drug regimen is not currently
recommended in children outside clinical trials. The lack of
CNS penetration of such regimens is of potential concern for
children with HIV encephalopathy [190,200,201].
12. Stopping treatment and
treatment interruptions
• Treatment interruptions cannot be routinely recommended
and starting ART currently means lifelong therapy.
• Judicious use of planned treatment interruptions may be
considered in circumstances when ART needs to be
stopped such as because of toxicity or adherence difficul-
ties, while the latter is being addressed.
• Stopping NNRTIs when HIV is fully suppressed requires a
replacement or staggered stop to reduce the risk of
developing NNRTI resistance as a result of the longer
half-life of NNRTIs. A replacement stop is preferable.
It is now clear that immune activation is a key component
of HIV immunopathogenesis, and is characterized by
polyclonal B- and T-cell activation, increased T-cell turn-
over, high levels of apoptosis and raised proinflammatory
cytokines and chemokines. Immune activation drives CD4
decline, immunosenescence and immune exhaustion.
The aetiology of HIV-related immune activation is multi-
factorial but includes immune responses to HIV and other
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reactivated chronic viral infections, direct T-cell activation
by HIV components, depletion of CD4 regulatory T cells
and translocation of microbial products across the gut
mucosa [202].
Many studies have shown that levels of immune activa-
tion are reduced but not normalized by ART, and it is the
ongoing inflammation that may underlie the noninfectious
complications of HIV infection such as heart and brain
disease. Indeed, the SMART trial, a large randomized CD4
cell count-driven treatment interruption study in adults,
was stopped early because of higher rates of non-AIDS-
related complications and deaths (cardiovascular, liver and
renal) in the treatment interruption arm as a result of
presumed increased levels of immune activation off ART
[51]. Largely because of the SMART trial results, treatment
interruptions are no longer recommended in adult patients.
In view of these studies in adults, studying treatment
interruptions in children has been difficult. However,
earlier ART initiation in children and commencement of
ART in all those diagnosed during infancy increase the
importance of addressing the question of whether children
can undergo periods off ART safely. There are many
reasons why children may have superior responses to inter-
mittent therapy than adults. These include the much lower
short-term risk of cardiovascular complications in children,
and the benefit of a more active thymus, which facilitates
improved capacity for immune reconstitution.
In a paediatric feasibility trial, PENTA 11, assessing clini-
cal, immunological and virological data for planned treat-
ment interruption (PTI) in older children with a median age
at entry of 9 years, there were no deaths or serious clinical
events in the treatment interruption arm [203]. By 2 years
after the end of the trial, when the majority of children
were back on ART, there was no difference in immuno-
logical recovery or viral suppression in the treatment inter-
ruption and continuous arms [204]. Independent predictors
of attaining a higher CD4 percentage after re-start of ART
were higher baseline CD4 percentage prior to PTI and
higher CD4 percentage prior to re-start of ART. Although
the PENTA 11 trial showed some evidence of immune
reactivation during PTI [205], this did not translate into
clinical events. Reassuringly, there was no difference in
height or weight gain and no difference in developmental
test scores between the two arms. In addition, most carers
and children reported better quality of life during PTI, and
the clinicians were more likely to re-start ART after PTI
with simpler regimens and FDCs [204].
Can treatment be interrupted after starting early ART in
infants? The CHER trial in South Africa showed that it is safe
to stop ART at 1 or 2 years of age where clinical, virological
and immunological parameters do not meet criteria for ART.
However, most of the children who stopped ART at 1 or 2
years of age needed to re-start in a median time of 33 weeks
or 70 weeks, respectively [36]. Nevertheless, nearly a third of
childrenwho stopped ART at 2 years of age were still off ART
at the end of the 6-year trial. Unfortunately, the study had no
comparator continuous treatment arm to ascertain whether
it is more advantageous to stay on continuous ART beyond
2 years of age. A small randomized trial in young Kenyan
children, with a median age of 30 months, comparing
continuous versus interrupted treatment after 2 years of
ART, was stopped early because a high proportion required
to re-start ART: 66% by 3months post interruption and 86%
by 18 months [206]. So, at present, ART interruption cannot
be routinely recommended even after ART has been started
in infancy.
Despite the recommendation for continuous therapy,
unplanned treatment interruptions in children as a result of
adherence difficulties or side effects of ART are common
[207]. Interruption of treatment occurred in nearly a quarter
of children and young people in the Adolescent Master
Protocol study in the USA [207]. In the light of such frequent
unplanned treatment interruptions, strategically planned
treatment interruptions may be preferable. Where possible,
this should be done safely to avoid development of resistance
to classes of drugs that could be used again in the future. The
options are a ‘staggered stop’, where the NRTI backbone is
continued for at least 7–10 days after stopping the NNRTI to
cover the ‘tail’, or a ‘replacement stop’, where the NNRTI is
replaced by a boosted PI before discontinuing the PI and
NRTIs simultaneously. There are no randomized comparisons
of these strategies; however, evaluation of emergent resist-
ance mutations in the SMART trial showed higher rates of
follow-up resistance mutations in patients undertaking a
simultaneous or staggered stop compared with a replacement
stop (although this did not reach statistical significance)
[208]. A replacement stop is therefore preferable. The EFV
‘tail’ may be longer compared with that of NVP because of
the longer half-life, and therefore the replacement stop may
need to be longer (21 days of the PI and NRTIs) [209].
Further studies of treatment interruptions in adults and
children may give better understanding of their place in
the management of HIV infection in children and young
people. The results of the Botswana/Baylor Antiretroviral
Assessment trial as well as a 5-year follow-up on immu-
nological and neurodevelopmental outcomes in PENTA 11
are awaited. Further research is needed to ascertain
whether PTI can reduce unplanned interruptions in older
children and young adults and be advantageous in terms of
reduction of resistance, preservation of future treatment
options and improvement of quality of life.
Might the case be different following early ART for
primary infection? The results of the Short Pulse Anti
Retroviral Therapy at HIV Seroconversion (SPARTAC) trial
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in adults, comparing short-term ART initiated during
primary HIV infection (ART for 48 weeks or 12 weeks)
versus standard of care (no ART), showed that a 48-week
course resulted in delayed decline of CD4 count and lower
VL off treatment as compared with standard care. Disap-
pointingly, time off treatment was not significantly longer
than the 48-week treatment period and the increase in CD4
count on long-term ART was similar across all three
groups. In contrast to the SMART trial, there were no
adverse effects on clinical outcomes [51,210]. Adult case
series from prospective observational cohort studies and
the results of the Agence Nationale de Recherche sur le
SIDA (ANRS) Virological and Immunological Studies in
Controllers after Treatment Interruption (VISCONTI) study
suggest that some patients with different genetic charac-
teristics and characteristic CD8 cell response to HIV, after
prolonged treatment of primary HIV infection, can control
HIV replication post treatment interruption for at least
several years [211,212]. It appears that restricting the pool
of HIV-infected cells by very early treatment might
decrease long-lived viral reservoirs [213], which may be
essential for successful control without therapy [212].
In addition to these adult studies, there is a case report of
ART-free ‘HIV remission’ for over 2 years in a child who
was started on ART at 36 hours after birth [214], and a
more recent report of an infected infant on continuous ART
treatment from 4 hours of age with undetectable proviral
DNA by 6 days of life [215]. Although the first patient has
now been reported as having detectable VL and has com-
menced ART [216], these reports together provide a proof
of concept that in some individuals, after early treatment of
primary infection, a prolonged treatment interruption may
be possible with preservation of control of HIV replication.
The phenomenon of post-treatment HIV controllers is rare
and treatment interruption cannot be applied to routine
management of children. Extensive research is being
undertaken to identify correlates for prolonged remission
in post-treatment controllers.
In summary, routine treatment interruptions cannot be
recommended at present and starting ART currently means
lifelong therapy. In circumstances where unplanned treat-
ment interruption is unavoidable, it needs to be done
safely, as outlined above. Strategic treatment interruption
may be considered in individual circumstances of problem-
atic adherence in order to avoid resistance and preserve
future treatment options.
13. Adolescence, mental health
and transition
Improved survival produced by ART, high rates of uptake
of antenatal HIV screening and successful interventions
reducing mother-to-child transmission have resulted in
an aging European paediatric population, with many
children born with HIV infection now transitioning to
adult care. Transition has been defined as ‘the planned
purposeful process that addresses the medical, psychoso-
cial and educational/vocational needs of adolescents
and young adults with chronic physical and medical
conditions as they move from child-centred to adult-
oriented health care systems’ [217]. In chronic diseases of
childhood no single model of transition has been shown
to be superior, although planned transition programmes
improve attendance, disease control, self-management
and patient and carer satisfaction. Data are emerging on
the transition preferences of HIV-infected adolescents,
with lack of confidence in negotiating adult services,
stigma associated with HIV and fear of ending lifelong
patient−carer relationships identified as barriers to tran-
sition [218–220]. Integrated paediatric and adult care in
an age-specific environment, increasing autonomy,
patient-centred timing of transition and comprehensive
management explanations facilitate transition to adult
care.
Data suggest that adolescents have poorer adherence to
ART when compared with younger children [221]. In ado-
lescents commencing first-line therapy, a boosted PI -based
regimen potentially reduces the risk of accumulating
resistance mutations in the event of virological failure;
however, such regimens have a higher pill burden than the
FDCs based on NNRTIs or EVG which have a lower genetic
barrier to resistance. Adolescents who suppress on a
boosted PI-based regimen can subsequently simplify to an
FDC once adherence has been established.
It is increasingly acknowledged that HIV-infected
young people have relatively high rates of mental health
disorder [98,222,223]. Whether these are higher than in
other patient groups with chronic medical conditions,
HIV-exposed but uninfected siblings or well-matched
healthy controls is yet to be fully determined [222,224–
226]. Nevertheless, it is essential that the multidiscipli-
nary team at least monitor for symptoms and signs of
psychological distress and mental health disorder, as chil-
dren progress into adolescence and young adult life.
Early and ongoing support from clinical psychologists
with specialist paediatric knowledge is recommended. The
possibility of other interventions including the wider
family and peer support should also be considered. Nego-
tiating adolescence with any chronic disease may be
difficult, but to do so with one potentially transmissible
to future partners and offspring before one has explored
one’s own sexuality adds a layer of complexity, often
compounded by stigma and secrecy associated with
HIV.
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Table 8 The paediatric antiretroviral pipeline
Compound Sponsor Formulation(s) and dose Status and comments
Nucleotide reverse transcriptase inhibitors
TAF Gilead Dose to be determined for
children
Under investigation in
adolescents with adult dose as a
component of EVG/COBI/FTC/TAF
(see below)
Phase II/III; EVG/COBI/FTC/TAF; treatment-naïve adolescents
aged 12 to < 18 years; enrolling
Co-formulation with FTC under discussion
Nonnucleoside reverse transcriptase inhibitors
ETR Janssen Dispersible tablets 25 (scored),
100 mg
Approved for 6 to18 years
Phase I /II; treatment-experienced children aged 2 months to
< 6 years and treatment-naïve children aged ≥ 2 months to < 2
years; enrolling
RPV Janssen Tablet 25 mg
Granules 2.5 mg /g
Phase II; adolescents aged 12 to < 18 years with
weight > 32 kg; enrolling
Phase I/II; children aged > 2 to < 12 years; planned
Protease inhibitors and combinations
ATV Bristol-Myers
Squibb (BMS)
Powder 50 mg sachet under
development
Capsules 100, 150, 200, 300 mg
Approved for 3 months and above by FDA
Phase III/IIIb; ongoing; RTV-boosted ATV for treatment-naïve
and -experienced children aged 3 months to < 6 years
Other studies in children aged up to 11 years ongoing
ATV/COBI Gilead/BMS Co-formulated boosted PIs in
development
Phase II/III; treatment-experienced children aged 3 months to
< 18 yearsDRV/COBI Gilead/ Janssen
LPV/r Cipla 40/10 mg pellets in capsules Submitted to FDA
LPV/r/3TC/ABC or ZDV DNDi/Cipla 4-in-1 FDC granules Formulation work ongoing
Booster
COBI Gilead 75 mg tablets
20 mg dispersible tablets for oral
suspension
As booster with ATV and DRV
Under development as component of EVG/COBI/FTC/TDF and
EVG/COBI/FTC/TAF
Integrase inhibitors and combinations
RAL Merck Granules for suspension 6 mg/kg
(100 mg sachet)
FDA approval for use in children 4 weeks of age and older
Neonate passive PK study ongoing (neonates born to women
who received RAL in pregnancy and during labour)
Neonate PK and safety study for prophylaxis; ongoing in
high-risk HIV-exposed neonates from birth to 6 weeks
EVG Gilead EVG reduced-strength tablets and
suspension in development
EVG PK; completed; RTV-boosted; adolescents aged 12 to < 18
years
RTV-boosted EVG to be studied in all age groups
EVG/COBI/FTC/TDF (Stribild) Gilead Reduced-strength tablets in
development
Studies underway in treatment-naïve adolescents aged 12 to
< 18 years
6 to < 12 years planned
(waiver < 6 years)
EVG/COBI/FTC/TAF Gilead Reduced-strength tablets in
development
Studies under way in treatment-naïve adolescents aged 12 to
< 18 years
6 to < 12 years planned
(waiver < 6 years)
DTG ViiV Healthcare Granule formulation in
development
Reduced-strength 10 mg and
25 mg tablets
Approved for adolescents aged 12 to < 18 years
weighing > 40 kg in USA and Europe
Phase I/II study; treatment-naïve and -experienced children
aged 6 weeks to < 18 years; ongoing
Exposures from granules were moderately higher than with
tablets and highest with formula milk in HIV-negative adults
DTG/ABC/3TC (572-Trii) ViiV Paediatric formulation
development planned
Dosing to be determined
Dependent on ongoing studies confirming DTG dose in children
and ability to establish appropriate dosing ratios for
components
CCR5 receptor antagonist
MVC ViiV Suspension 20 mg/mL Phase IV; treatment-experienced, CCR5 tropic children aged 2
to < 18 years
3TC, lamivudine; ABC, abacavir; ATV, atazanavir; COBI, cobicistat; DRV, darunavir; DTG, dolutegravir; ETR, etravirine; EVG, elvitegravir; FDA, US Food and Drug
Administration; FDC, fixed dose combination; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; RAL, raltegravir; TAF, tenofovir alafenamide; MVC, maraviroc; PI,
protease inhibitor; PK, pharmocokinetic; RPV, rilpivirine; RTV, ritonavir; ZDV, zidovudine.
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14. Pipeline and upcoming trials
There are considerable incentives and/or penalties from
regulatory agencies to ensure that any new drug that might
be of benefit to children must be studied in this population.
This is mandatory with both the EMA, which enforces
penalties for companies that do not provide a paediatric
investigational plan as part of their application (or request
a waiver), and the FDA, which also extends 6-month patent
protection to companies that perform requested paediatric
studies (voluntary).
Companies must include PK data for all age groups of
children, efficacy, tolerability, and differences in side effects.
They must have stability and palatability data for formula-
tions and demonstrate that they are able to achieve PK
targets associated with efficacy in adults. Most paediatric
development programmes take a staggered approach, start-
ing with the older cohorts of children and working down in
age. The studies are conducted in children as soon as there
are sufficient data from studies in adults. The current
paediatric antiretroviral pipeline is shown in Table 8; greater
detail can be found in the annually updated i-Base/TAG
Pipeline Report (available at http://www.pipelinereport.org).
Planned PENTA studies will look at two new drugs for
children in the integrase inhibitor class: DTG and EVG.
Supplementary table
A supplementary table is provided with a practical guide
to current PENTA ART drug dosing recommendations
(Supplementary Table S1).
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